{"gene":"IRF8","run_date":"2026-06-10T01:55:23","timeline":{"discoveries":[{"year":1996,"finding":"Targeted null mutation of ICSBP (IRF8) in mice causes immunodeficiency with impaired IFN-γ production and a CML-like myeloproliferative syndrome progressing to fatal blast crisis, establishing IRF8 as a regulator of hematopoietic progenitor cell proliferation and differentiation.","method":"Gene knockout mouse model (ICSBP-/- mice), bone marrow transfer, phenotypic analysis","journal":"Cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — clean KO with defined cellular phenotypes, replicated and foundational study widely cited","pmids":["8861914"],"is_preprint":false},{"year":1993,"finding":"The murine ICSBP gene contains a palindromic IFN response element (pIRE, TTCNNGGAA) in its promoter that confers IFN-γ induction via binding of the 91-kDa ISGF3α subunit (STAT1), establishing ICSBP as an IFN-γ-inducible gene regulated by STAT1.","method":"Gel mobility shift assay, heterologous promoter reporter assay, antibody supershift","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro binding assay with mutagenesis and reporter validation, foundational mechanistic study","pmids":["8321202"],"is_preprint":false},{"year":1995,"finding":"ICSBP contains at least three independent functional domains: a DNA-binding domain (DBD, aa 1-121), a transcriptional repressor domain, and an IRF-association domain (IAD) that mediates protein-protein interaction with IRF-1 and IRF-2 in vitro and in vivo.","method":"Domain deletion mutagenesis, VP16/GAL4 fusion constructs, electrophoretic mobility shift assay (EMSA), co-IP","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro reconstitution with mutagenesis and multiple orthogonal methods","pmids":["7768900"],"is_preprint":false},{"year":1994,"finding":"ICSBP acts as a conditional repressor of IFN-stimulated response element (ISRE)-containing promoters in hematopoietic cells; IRF-1 competes with ICSBP for ISRE binding and alleviates ICSBP-mediated repression, revealing a balance between positive (IRF-1) and negative (ICSBP) regulators of ISG expression.","method":"Reporter gene assay, EMSA competition assay","journal":"International immunology","confidence":"Medium","confidence_rationale":"Tier 1 / Weak — functional reporter and EMSA in single study, single lab","pmids":["7526889"],"is_preprint":false},{"year":2000,"finding":"ICSBP drives myeloid progenitor differentiation toward mature macrophages and represses granulocyte-specific genes; retroviral transduction of ICSBP into ICSBP-/- myeloid progenitors induced growth arrest, macrophage-specific gene expression, phagocytic activity, and inhibited G-CSF-mediated granulocytic differentiation.","method":"Retroviral transduction, in vitro differentiation assay, target DNA binding assay","journal":"Immunity","confidence":"High","confidence_rationale":"Tier 2 / Strong — loss-of-function rescue with retroviral expression, specific phenotypic readouts, replicated in multiple studies","pmids":["10981959"],"is_preprint":false},{"year":2000,"finding":"ICSBP (IRF8) is required for IL-12 p40 transcription in macrophages; it acts as a principal transcriptional activator of the IL-12 p40 promoter through the Ets binding site via protein-protein interaction, and synergizes with IRF-1. ICSBP-/- macrophage-like cells fail to induce IL-12 p40 after IFN-γ/LPS stimulation.","method":"Reporter gene assay, DNA affinity binding assay, endogenous mRNA induction, ICSBP-/- cell lines","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — multiple orthogonal methods, loss-of-function and gain-of-function, replicated across multiple studies","pmids":["10861061"],"is_preprint":false},{"year":2000,"finding":"ICSBP expression is downregulated by BCR-ABL in CML, and forced co-expression of ICSBP inhibits BCR-ABL-induced colony formation and CML-like disease in vivo, establishing ICSBP as a tumor suppressor that counteracts BCR-ABL-driven myeloproliferation.","method":"Retroviral transduction, colony formation assay, murine bone marrow transplantation model","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo murine CML model with both in vitro and in vivo readouts","pmids":["10648600"],"is_preprint":false},{"year":2002,"finding":"ICSBP is required for development of CD8α+ dendritic cells and mouse IFN-producing cells (plasmacytoid DC precursors) in vivo; ICSBP-/- mice lack CD8α+ DCs selectively, and this defect is intrinsic to bone marrow-derived progenitors.","method":"ICSBP-/- mouse analysis, bone marrow chimera experiments, flow cytometry, RT-PCR","journal":"The Journal of experimental medicine / Blood","confidence":"High","confidence_rationale":"Tier 2 / Strong — two independent groups (PMIDs 12461077 and 12393690) using KO mice and chimeras, replicated","pmids":["12461077","12393690"],"is_preprint":false},{"year":2002,"finding":"ICSBP's transcriptional function—requiring intact DNA-binding activity and ability to interact with partner proteins (PU.1 and other IRFs)—is essential for DC development and maturation; ICSBP mutants lacking either activity fail to rescue DC development from ICSBP-/- bone marrow.","method":"Retroviral transduction of ICSBP mutants into ICSBP-/- bone marrow, in vitro DC differentiation with Flt3 ligand","journal":"Blood","confidence":"High","confidence_rationale":"Tier 1 / Moderate — structure-function mutagenesis with defined rescue readout, single lab","pmids":["12393459"],"is_preprint":false},{"year":2002,"finding":"Upon IFN-γ stimulation, ICSBP interacts with the Ets protein TEL at the ISRE, recruiting histone deacetylase HDAC3 to the element, causing repression of ISRE-dependent transcription as a negative-feedback mechanism; this is distinct from ICSBP-PU.1 interactions at the EICE.","method":"Mass spectrometry of ISRE-bound proteins, in vitro binding with recombinant proteins, reporter assay, co-IP","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1 / Moderate — mass spectrometry identification plus in vitro reconstitution with recombinant proteins and reporter assay","pmids":["12370291"],"is_preprint":false},{"year":2002,"finding":"ICSBP and IRF-1 cooperatively stimulate murine IL-12 p40 promoter activity through a novel ISRE-like cis element (distinct from the Ets and NF-κB sites); mutation of this element abrogates ICSBP/IRF-1-driven activation.","method":"Reporter gene assay with promoter mutations, co-transfection in RAW 264.7 macrophages","journal":"FEBS letters","confidence":"Medium","confidence_rationale":"Tier 1 / Weak — functional reporter with mutagenesis, single lab","pmids":["12417340"],"is_preprint":false},{"year":2003,"finding":"NFAT physically associates with ICSBP in the absence of DNA (co-IP of endogenous proteins) and is required for ICSBP binding to the IL-12 p40 promoter; NFAT and ICSBP synergistically activate the p40 promoter, and this interaction is abrogated by IL-10.","method":"Co-immunoprecipitation of endogenous proteins, ChIP, reporter gene assay, dominant negative NFAT","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Moderate — reciprocal Co-IP of endogenous proteins plus ChIP and functional reporter, single lab","pmids":["12876285"],"is_preprint":false},{"year":2003,"finding":"ICSBP inhibits growth of BCR/ABL-transformed myeloid progenitor cells by transcriptionally repressing c-Myc indirectly through direct activation of Blimp-1 and METS/PE1 (potent c-Myc repressors), without affecting BCR/ABL kinase activity.","method":"Conditional ICSBP/ER chimera expression, mRNA expression analysis, ectopic Blimp-1 expression","journal":"Blood","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — conditional expression system with mechanistic dissection, single lab","pmids":["12933588"],"is_preprint":false},{"year":2003,"finding":"ICSBP antagonizes BCR/ABL and represses bcl-2 transcription via two ICSBP-responsive elements in the bcl-2 promoter, as shown by reporter gene assays and EMSA; ICSBP overcomes BCR/ABL-induced morphology changes, chemotherapy resistance, and repression of differentiation.","method":"Reporter gene assay, EMSA, stable/conditional ICSBP expression in BCR/ABL-transformed cells","journal":"Blood","confidence":"Medium","confidence_rationale":"Tier 1-2 / Moderate — reporter and EMSA plus functional in vivo model, single lab","pmids":["14656881"],"is_preprint":false},{"year":2003,"finding":"ICSBP is critically required for development and trafficking of Langerhans cells and dermal DCs; ICSBP-/- DCs show reduced CCR6 and CCR7 expression, impaired migratory response to MIP-3α, MIP-3β, and CCL21, and failure to initiate contact hypersensitivity responses.","method":"ICSBP-/- mouse analysis, in vitro migration assay, RT-PCR for chemokine receptors, contact hypersensitivity model","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 / Moderate — KO mouse with defined cellular phenotype and mechanistic pathway (chemokine receptor expression), single lab","pmids":["14615368"],"is_preprint":false},{"year":2004,"finding":"ICSBP/IRF-8 cooperates with PU.1 to activate transcription of the p15(Ink4b) cyclin-dependent kinase inhibitor gene; both ICSBP and PU.1 must bind DNA to form a stable complex at the p15 promoter, providing a mechanism for ICSBP tumor suppressor activity in myeloid cells.","method":"Reporter gene assay, EMSA (PU.1/ICSBP binding complex), ICSBP transduction into ICSBP-null cells","journal":"Blood","confidence":"Medium","confidence_rationale":"Tier 1-2 / Moderate — functional reporter with EMSA and gain-of-function, single lab","pmids":["14976051"],"is_preprint":false},{"year":2005,"finding":"The BXH-2 mouse carries an R294C substitution in the IRF association domain (IAD) of IRF8/ICSBP; this loss-of-function mutation impairs IL-12 production and causes myeloproliferation and immunodeficiency, confirming the IAD is essential for IRF8 function.","method":"Positional cloning, sequencing, transactivation reporter assay in RAW 264.7 macrophages","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 2 / Strong — identified causal mutation, confirmed by functional assay, replicated by multiple studies","pmids":["15781580"],"is_preprint":false},{"year":2007,"finding":"The IRF8 R294C mutation (BXH2) abolishes interaction of IRF8 with partner transcription factors and prevents binding to promoters requiring partner interactions, selectively eliminating CD8α+ DC development and IL-12p40 production while retaining pDC development and type I IFN production.","method":"EMSA, chromatin immunoprecipitation (ChIP), flow cytometry of DC subsets in BXH2 mice","journal":"Blood","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — EMSA plus ChIP plus in vivo phenotyping, mechanistic separation of DC subsets established","pmids":["18055870"],"is_preprint":false},{"year":2007,"finding":"IRF8 binds to a variant in the CHRNA1 promoter and activates CHRNA1 transcription in thymic epithelial cells; the K108E disease-associated variant prevents IRF8 binding and abrogates promoter activity, demonstrating IRF8 controls thymic promiscuous expression of a self-antigen.","method":"Promoter reporter assay in thymic epithelial cells, EMSA, in vitro mutagenesis","journal":"Nature","confidence":"Medium","confidence_rationale":"Tier 1-2 / Moderate — reporter assay and EMSA in primary and cell line contexts, single lab","pmids":["17687331"],"is_preprint":false},{"year":2008,"finding":"IRF8 binds directly to IRF8/Ets consensus sequences in the promoters of Sfpi1 (encoding PU.1) and Ebf1, repressing Sfpi1 and activating Ebf1; a signaling-deficient IRF8 mutant fails to rescue B-cell lineage specification from IRF8-/- HSCs.","method":"ChIP, reporter gene assay, retroviral transduction of IRF8 mutants into IRF8-/- HSCs","journal":"Blood","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — ChIP plus functional rescue with mutant, single lab, multiple methods","pmids":["18799728"],"is_preprint":false},{"year":2008,"finding":"ICSBP represses PTPN13 (Fap-1) transcription via a cis element in its proximal promoter in myeloid cells; this repression is regulated by phosphorylation of conserved tyrosine residues in the IRF domain of ICSBP, and loss of ICSBP increases Fap-1, resulting in Fas dephosphorylation and apoptosis resistance.","method":"CpG island microarray ChIP screen, reporter gene assay, phosphorylation mutants, apoptosis assays","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 1-2 / Moderate — ChIP identification followed by reporter and mutagenesis, single lab","pmids":["18195016"],"is_preprint":false},{"year":2007,"finding":"ICSBP/IRF-8 cooperates with PU.1 and IRF-2 to activate NF1 transcription via a composite ets/IRF cis element; PU.1 binds DNA first, recruits IRF-2 (requiring phosphorylation of specific serine residues in PU.1 PEST domain and an IRF domain tyrosine in IRF-2), and ICSBP then interacts with the DNA-bound PU.1-IRF-2 heterodimer (requiring its own conserved IRF domain tyrosine).","method":"EMSA, reporter gene assay, phosphorylation mutant analysis","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — in vitro binding assay with mutagenesis, functional reporter, single lab","pmids":["17200120"],"is_preprint":false},{"year":2010,"finding":"ICSBP/IRF8 decreases β-catenin activity in myeloid cells by repressing GAS2 transcription (via ICSBP/Tel/HDAC3 complex at GAS2 promoter); Gas2 inhibits calpain protease, and β-catenin is a calpain substrate, so ICSBP loss elevates Gas2, inhibits calpain, and increases β-catenin protein and activity.","method":"ChIP (ICSBP/Tel/HDAC3 at GAS2 promoter), reporter gene assay, calpain activity assay, β-catenin protein quantification","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — ChIP plus biochemical pathway dissection with multiple orthogonal methods, single lab","pmids":["20679491"],"is_preprint":false},{"year":2011,"finding":"IRF8 regulates acid ceramidase (A-CDase) expression by directly binding to its promoter; loss of IRF8 increases A-CDase protein, leading to reduced C16 ceramide and resistance to FasL-induced apoptosis in CML cells, while restoration of IRF8 suppresses CML via a Fas-dependent mechanism.","method":"ChIP (IRF8 binding to A-CDase promoter), reporter assay, ceramide measurement, apoptosis assay, in vivo CML model","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — ChIP plus in vitro and in vivo functional readouts, single lab, multiple methods","pmids":["21487040"],"is_preprint":false},{"year":2011,"finding":"IRF8 is required for IFN-β induction in human blood monocytes by cooperating with IRF3; IRF8 constitutively binds the EICE of the IFN-β promoter together with PU.1 in vivo, forming a scaffold that facilitates recruitment of IRF3. The protein-protein interaction between IRF8 and IRF3 is independent of both the DBD of IRF8 and the IAD of IRF3.","method":"siRNA knockdown in primary monocytes, ChIP, co-IP to map interaction domains, retroviral rescue in IRF8-/- cell line","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 / Moderate — reciprocal Co-IP with domain mapping plus ChIP and functional rescue, single lab","pmids":["21228327"],"is_preprint":false},{"year":2011,"finding":"IRF-8 extinguishes neutrophil production and promotes DC lineage commitment in both myeloid and lymphoid progenitors in a cell-intrinsic manner; retroviral expression of IRF-8 in GMP (which does not normally generate DCs) suppressed neutrophil production and increased DC output.","method":"Irf8-/- competitive bone marrow reconstitution, retroviral overexpression in multiple progenitor types","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 / Strong — cell-intrinsic competitive reconstitution plus gain-of-function in multiple progenitor types, replicated findings","pmids":["22238324"],"is_preprint":false},{"year":2011,"finding":"IRF8 acts as a negative regulator of osteoclastogenesis; TLR ligands and cytokines induce IRF8 expression to inhibit osteoclast differentiation, placing IRF8 in a feedback inhibition circuit.","method":"Loss-of-function analysis in osteoclast differentiation assays, IRF8 induction by TLR ligands/cytokines","journal":"Annals of the New York Academy of Sciences","confidence":"Low","confidence_rationale":"Tier 3 / Weak — review/commentary format with limited primary experimental detail in abstract","pmids":["22082370"],"is_preprint":false},{"year":2013,"finding":"G-CSF and GM-CSF (MDSC-inducing factors) downregulate IRF-8 expression in myeloid cells via STAT3- and STAT5-dependent pathways, and IRF-8 overexpression attenuates MDSC accumulation, establishing STAT3/STAT5 as writers that suppress IRF8 to drive MDSC development.","method":"IRF-8 overexpression mouse model, Irf8-/- phenotyping, pathway analysis of STAT3/STAT5 signaling","journal":"The Journal of clinical investigation","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic models plus defined cytokine pathways, single lab","pmids":["24091328"],"is_preprint":false},{"year":2013,"finding":"IRF8 and PU.1 form a complex that controls plasma cell differentiation by concurrently promoting BCL6 and PAX5 expression and repressing AID and BLIMP-1; IRF8-PU.1 complex functions reciprocally to IRF4.","method":"Genetic loss-of-function (conditional KO), reporter assay, gene expression profiling","journal":"The Journal of experimental medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — conditional KO with transcriptional target analysis, single lab","pmids":["25288399"],"is_preprint":false},{"year":2013,"finding":"Wnt/β-catenin signaling activates Irf8 expression in normal hematopoiesis, and IRF8 in turn limits oncogenic β-catenin functions; combined Irf8 deletion and constitutive β-catenin activation drive CML blast crisis, establishing a cross-talk circuit.","method":"Mouse genetics (Irf8 conditional KO combined with activated β-catenin alleles), BCR-ABL CML model","journal":"The Journal of experimental medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic epistasis with defined in vivo phenotypes, single lab","pmids":["24101380"],"is_preprint":false},{"year":2015,"finding":"IRF8 directly activates genes involved in multiple steps of autophagy in macrophages, promotes autophagosome formation and lysosomal fusion; Irf8-/- macrophages accumulate SQSTM1 and ubiquitin-bound proteins and fail to clear Listeria monocytogenes via autophagy.","method":"Irf8-/- macrophage analysis, ChIP (IRF8 at autophagy gene promoters), autophagic flux assay, bacterial clearance assay","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Moderate — ChIP plus functional autophagic flux and bacterial clearance assays in KO context, single lab, multiple methods","pmids":["25775030"],"is_preprint":false},{"year":2015,"finding":"Icsbp/IRF8 is required to terminate emergency granulopoiesis by repressing Fap1 and Gas2 and activating Fanconi C and F genes; loss of Icsbp results in sustained granulocyte production, resistance to Fas-induced apoptosis, increased β-catenin activity, and accelerated progression to AML.","method":"Icsbp-/- mouse emergency granulopoiesis model, gene expression analysis, apoptosis assay","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — KO mouse model with mechanistic target gene analysis, single lab","pmids":["26683374"],"is_preprint":false},{"year":2016,"finding":"SIRT1 physically interacts with IRF8 and deacetylates it in macrophages; LPS treatment decreases SIRT1 expression and increases IRF8 expression, and LPS-induced IRF8 expression is abrogated when SIRT1 is specifically deleted.","method":"Co-immunoprecipitation, immunofluorescence, SIRT1 conditional KO macrophages","journal":"Innate immunity","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — Co-IP plus KO phenotype, single lab","pmids":["28008797"],"is_preprint":false},{"year":2017,"finding":"IRF8 controls Th9 differentiation through a transcription factor complex of IRF8, IRF4, PU.1, and BATF that binds DNA and activates Il9 transcription; IRF8 also dimerizes with ETV6 to repress Il4 expression.","method":"In vitro and in vivo Th9 differentiation assays (IRF8-deficient mice), ChIP, co-IP for complex components","journal":"Nature communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP and Co-IP with defined complex, KO phenotype in vivo, single lab","pmids":["29233972"],"is_preprint":false},{"year":2018,"finding":"IRF8 governs the transcription of Naip genes (NLRC4 inflammasome sensors for flagellin and T3SS components) in macrophages, enabling NLRC4 inflammasome activation; IRF8 is required for optimal NLRC4 inflammasome activation against Salmonella, Burkholderia, and Pseudomonas but is dispensable for NLRP3, AIM2, and Pyrin inflammasome activation.","method":"Irf8-/- bone marrow-derived macrophages, infection assays, RNA-seq, ChIP, caspase-1 activation assay","journal":"Cell","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — KO macrophages with multiple pathogens, ChIP for direct binding, selective inflammasome specificity established with multiple orthogonal methods","pmids":["29576451"],"is_preprint":false},{"year":2018,"finding":"Cell-intrinsic IRF8 is required for NK cell-mediated protection against MCMV; during viral exposure, NK cells upregulate IRF8 through IL-12 signaling via STAT4, which promotes epigenetic remodeling of the Irf8 locus; IRF8 then promotes NK cell proliferation by inducing cell-cycle genes and directly controlling Zbtb32.","method":"Cell-intrinsic KO, IL-12 signaling analysis, STAT4 requirement, epigenetic analysis of Irf8 locus, MCMV infection model","journal":"Immunity","confidence":"High","confidence_rationale":"Tier 2 / Strong — cell-intrinsic KO with defined signaling pathway (IL-12/STAT4/IRF8/Zbtb32), epigenetic and functional readouts","pmids":["29858012"],"is_preprint":false},{"year":2018,"finding":"Tumor-produced granulocyte-stimulating factor downregulates IRF8 in cDC progenitors, resulting in reduced cDC1 development and impaired anti-tumor CD8+ T-cell responses.","method":"Mouse tumor models (breast, pancreatic), bone marrow progenitor analysis, IRF8 expression measurement, CD8+ T-cell functional assays","journal":"Nature communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — mechanistic pathway identified in vivo with functional immune readout, single lab","pmids":["29593283"],"is_preprint":false},{"year":2019,"finding":"A +41-kb Irf8 enhancer transiently accessible in cDC1 progenitors is required for induction of Irf8 in CDPs and cDC1 fate specification; a separate +32-kb Irf8 enhancer is required for cDC1 maturation but not specification. CRISPR/Cas9 deletion of these enhancers distinguishes their roles.","method":"CRISPR/Cas9 genome editing of enhancers, chromatin profiling (ATAC-seq), in vivo DC development analysis","journal":"Nature immunology","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — CRISPR enhancer deletion with chromatin profiling, two enhancers functionally distinguished","pmids":["31406378"],"is_preprint":false},{"year":2019,"finding":"An Nfil3-Zeb2-Id2 genetic circuit controls the switch from the +41-kb to +32-kb Irf8 enhancer during cDC1 development; Nfil3 is required for the transition from Zeb2hi/Id2lo to Zeb2lo/Id2hi CDPs (earliest committed cDC1 progenitors), excluding pDC potential.","method":"Single-cell RNA sequencing of CDPs, genetic epistasis analysis (Nfil3, Zeb2, Id2 KO combinations), enhancer accessibility","journal":"Nature immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — scRNA-seq plus genetic epistasis with multiple KO combinations, replicated in companion paper","pmids":["31406377"],"is_preprint":false},{"year":2019,"finding":"IRF8 deletion in committed cDC1 cells (via Xcr1-Cre) causes their transcriptional, functional, and epigenetic reprogramming into cDC2-like cells, indicating IRF8 is continuously required to maintain cDC1 identity; this conversion was independent of Irf4.","method":"Xcr1-Cre conditional IRF8 deletion, RNA-seq, ATAC-seq, functional assays","journal":"Immunity","confidence":"High","confidence_rationale":"Tier 2 / Strong — conditional KO in committed cells with transcriptome and chromatin accessibility profiling, epistasis with Irf4","pmids":["35830859"],"is_preprint":false},{"year":2021,"finding":"ZMYND8 directly activates IRF8 through lineage-specific enhancers in AML; ZMYND8 occupancy at IRF8 enhancers requires BRD4 (a transcription coactivator), and ZMYND8 binds to the ET domain of BRD4 via its chromatin reader cassette, establishing an IRF8-MEF2D transcriptional circuit as an AML dependency.","method":"ChIP-seq (ZMYND8, BRD4, IRF8 enhancers), in vitro and in vivo ZMYND8 KO, protein interaction mapping","journal":"Molecular cell","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — ChIP-seq with mechanistic protein-interaction mapping and in vivo functional validation, single lab","pmids":["34358447"],"is_preprint":false},{"year":2021,"finding":"A RUNX-CBFβ-driven enhancer 56 kb downstream of the Irf8 transcription start site controls Irf8 expression throughout the myeloid lineage; deletion of this enhancer decreases IRF8 throughout myeloid progenitors, resulting in loss of cDC progenitors and overproduction of Ly6C+ monocytes, and demonstrates that IRF8 expression level (high/low/null) dose-dependently directs cDC1/monocyte/neutrophil fate via distinct sets of enhancers.","method":"In vivo CRISPR enhancer deletion, scRNA-seq, ATAC-seq, flow cytometric lineage analysis","journal":"Nature immunology","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — in vivo enhancer deletion with chromatin profiling and dose-dependent lineage analysis","pmids":["33603226"],"is_preprint":false},{"year":2021,"finding":"Brd4 forms a complex with IRF8/PU.1 and binds to IRF8 and PU.1 binding motifs on Naip promoters to maintain Naip expression; Brd4-deficient macrophages show impaired NLRC4 inflammasome activation and reduced Naip transcription.","method":"Co-IP (Brd4/IRF8/PU.1 complex), ChIP, Brd4-/- macrophage infection assay, RNA-seq","journal":"The Journal of cell biology","confidence":"High","confidence_rationale":"Tier 2 / Moderate — Co-IP for complex plus ChIP and KO functional assay, single lab","pmids":["33535228"],"is_preprint":false},{"year":2022,"finding":"IRF8 promotes STING-mediated innate immune responses in monocytes through a transcription-independent mechanism: in uninfected cells IRF8 is inactive (IAD sequestered by N- and C-terminal tails); upon cGAS-STING pathway activation, IRF8 is phosphorylated at Serine 151, enabling its IRF-association domain to bind STING, promoting STING polymerization and TBK1-mediated phosphorylation of STING and IRF3.","method":"Phospho-mutant analysis, co-IP, IRF8-deficient monocytes, HSV-1 infection model, STING polymerization assay","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — phospho-mutant with biochemical reconstitution (STING polymerization, TBK1 phosphorylation), disease-relevant patient correlation, multiple orthogonal methods","pmids":["35973990"],"is_preprint":false},{"year":2022,"finding":"TAM-specific IRF8 is required for tumor-associated macrophages to present cancer cell antigens and promote CTL exhaustion in tumors; TAM-specific IRF8 deletion prevented exhaustion of cancer-reactive CTLs and suppressed tumor growth.","method":"TAM-specific conditional IRF8 deletion, antigen presentation assays, CTL exhaustion markers, tumor growth assay","journal":"Immunity","confidence":"High","confidence_rationale":"Tier 2 / Strong — cell-type-specific conditional KO with defined antigen presentation and exhaustion phenotypes, in vivo tumor suppression","pmids":["36288724"],"is_preprint":false},{"year":2022,"finding":"IRF8 suppresses T-ALL by inhibiting the PI3K/AKT signaling pathway; FTO (m6A demethylase) binds to m6A sites in the 3' UTR of IRF8 mRNA and promotes its degradation, silencing IRF8 in T-ALL cells.","method":"IRF8 overexpression/KO in T-ALL cells, PI3K/AKT signaling analysis, m6A-seq, RIP-seq (FTO binding to IRF8 mRNA), FTO inhibition in vivo","journal":"Advanced science","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — m6A-seq and RIP-seq identification of post-transcriptional regulation plus functional pathway validation, single lab","pmids":["36478193"],"is_preprint":false},{"year":2024,"finding":"IRF8 binds stepwise to enhancer regions in postnatal microglia together with Sall1 and PU.1, reaching maximum binding after day 14; IRF8 binding correlates with stepwise increases in chromatin accessibility preceding microglial-specific transcriptome initiation; IRF8 is also required for microglial-specific DNA methylation patterns. Constitutive or postnatal Irf8 deletion causes loss of microglial identity and gain of disease-associated microglia (DAM)-like gene expression.","method":"ChIP-seq, ATAC-seq, scRNA-seq, scATAC-seq, conditional Irf8 deletion (constitutive and postnatal), bisulfite sequencing (DNA methylation), 5xFAD model","journal":"Nature immunology","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — multiple orthogonal epigenomic methods (ChIP-seq, ATAC-seq, methylation) plus conditional KO with single-cell resolution","pmids":["39313544"],"is_preprint":false},{"year":2020,"finding":"IRF8 deficiency causes cDC2 heterogeneity through two distinct pathways: a lymphoid-primed IRF8hi pathway (marked by CD123 and BTLA) carries pDC, cDC1, and DC2 trajectories, while a common myeloid IRF8lo pathway (SIRPA+) generates DC3s and monocytes; DC3s expand to replace DC2s in human partial IRF8 deficiency.","method":"Human IRF8-deficiency allelic series, high-dimensional flow cytometry, in vitro differentiation from human stem cells","journal":"Immunity","confidence":"High","confidence_rationale":"Tier 2 / Strong — human genetic loss-of-function series with in vitro differentiation and high-dimensional analysis","pmids":["32735845"],"is_preprint":false},{"year":2018,"finding":"IRF8 promotes NLRP3 inflammasome activation during Gram-negative bacterial infection by mediating phosphorylation of IRF3, which is required for Ifnb transcription; IFN-β in turn triggers caspase-11-dependent NLRP3 inflammasome activation. IRF8 was previously shown to be dispensable for caspase-11-mediated NLRP3 activation during LPS transfection.","method":"IRF8-/- bone marrow-derived macrophages, caspase-1/caspase-11 activation assays, Gram-negative bacterial infection, IRF3 phosphorylation analysis","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — KO macrophages with defined signaling pathway (IRF8→IRF3 phosphorylation→IFN-β→caspase-11→NLRP3), single lab","pmids":["32205422"],"is_preprint":false},{"year":2019,"finding":"IRF8 inhibits osteoclastogenesis; an IRF8 G388S mutation promotes osteoclastogenesis and fails to inhibit NFATc1-dependent transcriptional activation; IRF8 constitutively binds regulatory regions of thousands of genes in osteoclast precursors and its loss enhances osteoclast-specific transcripts.","method":"Functional osteoclastogenesis assay, NFATc1 reporter assay, ChIP-seq in osteoclast precursors, Irf8+/- mouse alveolar bone analysis","journal":"Journal of bone and mineral research","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — ChIP-seq plus functional mutant assay plus in vivo mouse phenotype, single lab","pmids":["30840779"],"is_preprint":false},{"year":2021,"finding":"PU.1 and IRF8 bind to an Ets/IRF composite element (EICE) in the distal promoter of human NLRP3, controlling its monocytic lineage-specific expression; knockdown of PU.1 and/or IRF8 downregulates NLRP3 expression and markedly diminishes LPS-induced IL-1β release.","method":"Reporter assay, EMSA, ChIP, siRNA knockdown in THP-1 and primary macrophages","journal":"Frontiers in immunology","confidence":"Medium","confidence_rationale":"Tier 1-2 / Moderate — EMSA and ChIP with functional KD readout, single lab","pmids":["33897697"],"is_preprint":false},{"year":2018,"finding":"IRF8 and PU.1 are required for microglial activation; both factors directly target each other's gene transcription in a positive feedback loop; IRF8 and PU.1 cooperatively bind composite IRF-ETS motifs on microglial activation-related genes, verified biochemically by synergistic binding to composite-motif DNA.","method":"Post-developmental conditional deletion in microglia, 3D fluorescence imaging, ChIP, biochemical DNA-binding assay","journal":"Protein & cell","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — conditional KO with biochemical binding confirmation, single lab","pmids":["30484118"],"is_preprint":false},{"year":2012,"finding":"miR-22 directly targets the 3' UTR of Irf8 mRNA for post-transcriptional repression, controlling DC subset differentiation; miR-22 overexpression enhanced cDC generation at the expense of pDCs while reducing Irf8 mRNA abundance.","method":"Luciferase reporter assay (miR-22 binding Irf8 3' UTR), miR-22 overexpression/knockdown during DC development","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — luciferase reporter with mutagenesis plus gain/loss-of-function in DC development, single lab","pmids":["23251709"],"is_preprint":false}],"current_model":"IRF8 (ICSBP) is an IFN-γ-inducible transcription factor that operates through combinatorial interactions with PU.1, IRF-1, IRF-2, IRF-3, IRF-4, BATF, NFAT, and other partners via its IRF-association domain (IAD) and DNA-binding domain, binding ISRE, EICE, and GAS elements to control myeloid lineage commitment (promoting monocytes/macrophages/DCs while suppressing neutrophils), DC subset specification (requiring lineage-specific +41-kb and +32-kb Irf8 enhancers activated by RUNX-CBFβ or E-protein circuits), NK and B cell maturation, inflammasome activation (by transcribing Naip genes for NLRC4), autophagy gene expression, and microglial identity (by establishing enhancer chromatin accessibility and DNA methylation), and also functions transcription-independently by being phosphorylated at Ser151 to associate with STING and promote its polymerization and TBK1-mediated innate immune signaling."},"narrative":{"mechanistic_narrative":"IRF8 (ICSBP) is an IFN-γ-inducible transcription factor that serves as a master regulator of myeloid and dendritic cell fate, hematopoietic homeostasis, and innate immunity [PMID:8861914, PMID:8321202]. Its induction is driven by STAT1 acting through a palindromic IFN response element in the Irf8 promoter [PMID:8321202], and it operates through three functional modules: a DNA-binding domain, a transcriptional repressor domain, and an IRF-association domain (IAD) that mediates combinatorial partnerships with other transcription factors [PMID:7768900]. Through these partnerships—with PU.1, IRF-1, IRF-2, IRF-3, IRF-4, BATF, NFAT, and the Ets factor TEL—IRF8 binds ISRE, EICE, and composite Ets/IRF elements to either activate or repress targets depending on partner context, including TEL/HDAC3-mediated repressive feedback at the ISRE [PMID:7768900, PMID:12370291, PMID:12876285, PMID:17200120, PMID:21228327, PMID:29233972]. At the lineage level IRF8 drives differentiation of monocytes, macrophages, and dendritic cells while extinguishing neutrophil/granulocyte production, with dose-dependent enhancer usage (a RUNX-CBFβ-driven +56-kb enhancer for the broad myeloid program, transient +41-kb and +32-kb enhancers for cDC1 specification versus maturation) determining cDC1, monocyte, or neutrophil fate, and continuous IRF8 activity required to maintain committed cDC1 identity [PMID:10981959, PMID:22238324, PMID:31406378, PMID:31406377, PMID:35830859, PMID:33603226]. IRF8 functions as a myeloid tumor suppressor that antagonizes BCR-ABL-driven myeloproliferation by activating cell-cycle and pro-apoptotic programs (p15Ink4b, Blimp-1, acid ceramidase) and repressing growth-promoting targets (c-Myc, bcl-2, β-catenin via Gas2), and its loss accelerates progression to blast crisis and AML [PMID:10648600, PMID:12933588, PMID:14656881, PMID:14976051, PMID:20679491, PMID:21487040, PMID:26683374]. In innate immunity IRF8 transcribes Naip genes to license NLRC4 inflammasome activation, drives autophagy gene expression for bacterial clearance, and cooperates with IRF3 for IFN-β induction [PMID:25775030, PMID:29576451, PMID:33535228, PMID:21228327]. Beyond transcription, IRF8 acts non-transcriptionally in the cGAS-STING pathway: phosphorylation at Ser151 releases its IAD to bind STING, promoting STING polymerization and TBK1-mediated signaling [PMID:35973990]. IRF8 also establishes and maintains microglial identity through stepwise enhancer activation, chromatin accessibility, and DNA methylation alongside Sall1 and PU.1 [PMID:39313544, PMID:30484118]. Human IRF8 deficiency produces a graded loss of dendritic cell subsets [PMID:32735845].","teleology":[{"year":1993,"claim":"Establishing how IRF8 is itself controlled, the discovery that its promoter carries a STAT1-bound IFN response element defined IRF8 as a downstream effector of IFN-γ signaling.","evidence":"Gel shift, reporter assays, and antibody supershift on the murine ICSBP promoter","pmids":["8321202"],"confidence":"High","gaps":["Did not address IRF8's own transcriptional targets","Other inducing signals beyond IFN-γ/STAT1 not mapped"]},{"year":1995,"claim":"Dissecting the protein into a DNA-binding domain, a repressor domain, and an IRF-association domain explained how IRF8 could act through partner-dependent combinatorial assemblies.","evidence":"Domain deletion mutagenesis, GAL4/VP16 fusions, EMSA, and co-IP with IRF-1 and IRF-2","pmids":["7768900"],"confidence":"High","gaps":["Did not establish in vivo physiological partners","Structural basis of IAD interaction not resolved"]},{"year":1996,"claim":"The null mouse demonstrated that IRF8 is essential for hematopoietic homeostasis, linking its loss to a CML-like myeloproliferative syndrome and immunodeficiency.","evidence":"ICSBP-/- knockout mice with bone marrow transfer and phenotypic analysis","pmids":["8861914"],"confidence":"High","gaps":["Did not identify the direct target genes underlying myeloproliferation","Cell-intrinsic versus environmental contributions not separated"]},{"year":2000,"claim":"Gain-of-function and target studies showed IRF8 actively drives macrophage differentiation while repressing granulocyte genes and is the principal activator of IL-12 p40, defining its myeloid lineage-instructive role.","evidence":"Retroviral rescue of ICSBP-/- progenitors, differentiation assays, and IL-12 p40 promoter reporter/binding assays","pmids":["10981959","10861061"],"confidence":"High","gaps":["Full set of macrophage versus granulocyte target genes incomplete","Mechanism of partner selection at distinct promoters unresolved"]},{"year":2000,"claim":"Demonstrating IRF8 downregulation by BCR-ABL and its suppression of CML in vivo established IRF8 as a bona fide myeloid tumor suppressor.","evidence":"Retroviral co-expression with BCR-ABL, colony formation, and murine bone marrow transplantation","pmids":["10648600"],"confidence":"High","gaps":["Direct transcriptional targets mediating tumor suppression not yet defined at this stage"]},{"year":2003,"claim":"Mechanistic dissection revealed IRF8's tumor-suppressive output operates through repression of c-Myc (via Blimp-1/METS), bcl-2, and PTPN13/Fap-1, and activation of p15Ink4b, linking IRF8 to growth arrest and apoptosis sensitivity.","evidence":"Conditional ICSBP/ER systems, reporter assays, EMSA, and apoptosis assays in BCR/ABL-transformed cells","pmids":["12933588","14656881","14976051","18195016"],"confidence":"Medium","gaps":["Direct versus indirect target relationships partly inferred","Single-lab findings for several targets"]},{"year":2002,"claim":"Identifying partner-dependent activity—NFAT and TEL/HDAC3 associations, plus the requirement for DNA binding and IRF interaction—explained how IRF8 toggles between activation and repression at the same elements.","evidence":"Mass spectrometry of ISRE-bound proteins, co-IP, ChIP, reporter assays, and mutant rescue in DC differentiation","pmids":["12370291","12876285","12393459","12417340"],"confidence":"High","gaps":["Determinants of repressive versus activating partner recruitment not fully defined","Some interactions characterized in single labs"]},{"year":2002,"claim":"Knockout and chimera studies established IRF8's selective requirement for CD8α+ DC and plasmacytoid DC development, anchoring its role in DC subset specification.","evidence":"ICSBP-/- mouse and bone marrow chimera analysis with flow cytometry and RT-PCR","pmids":["12461077","12393690"],"confidence":"High","gaps":["Enhancer-level control of subset specification not yet known","Did not resolve dose-dependence of fate decisions"]},{"year":2005,"claim":"The BXH2 R294C IAD mutation linked a specific lesion to loss of partner interaction, IL-12 defects, and myeloproliferation, proving the IAD is functionally essential in vivo.","evidence":"Positional cloning, sequencing, transactivation reporter assays, and DC subset phenotyping in BXH2 mice","pmids":["15781580","18055870"],"confidence":"High","gaps":["Why pDC development is spared while CD8α+ DC is lost not fully explained mechanistically"]},{"year":2008,"claim":"Direct binding studies in B-cell and myeloid contexts showed IRF8 regulates lineage transcription factors (Sfpi1/PU.1, Ebf1) and forms composite complexes with PU.1 and IRF-2, formalizing its combinatorial logic in lineage specification.","evidence":"ChIP, reporter assays, and mutant rescue in IRF8-/- HSCs; EMSA with phosphorylation mutants","pmids":["18799728","17200120","28008797"],"confidence":"High","gaps":["Post-translational control of partner recruitment (Tyr/Ser phosphorylation, deacetylation) only partly mapped"]},{"year":2013,"claim":"Multiple studies positioned IRF8 within signaling circuits controlling its abundance—STAT3/STAT5 and tumor-derived G-CSF suppress it to drive MDSC/cDC defects, while Wnt/β-catenin activates it—linking IRF8 levels to immune and oncogenic outcomes.","evidence":"Genetic models, cytokine pathway analysis, tumor models, and β-catenin epistasis","pmids":["24091328","29593283","24101380","29233972"],"confidence":"Medium","gaps":["Quantitative thresholds of IRF8 needed for each outcome not defined here","Several single-lab mechanisms"]},{"year":2015,"claim":"IRF8 was shown to directly transcribe autophagy genes and (with PU.1) Naip/NLRP3 inflammasome components, extending its role from lineage control to effector innate immune functions.","evidence":"ChIP, autophagic flux and bacterial clearance assays, infection assays, and caspase activation in Irf8-/- macrophages","pmids":["25775030","29576451","33897697","32205422","33535228"],"confidence":"High","gaps":["Selectivity for NLRC4 versus other inflammasomes mechanistically partial","Brd4 contribution to Naip control single-lab"]},{"year":2018,"claim":"Cell-intrinsic studies defined an IL-12/STAT4/IRF8/Zbtb32 axis driving NK cell proliferation and antiviral protection through epigenetic remodeling of the Irf8 locus, broadening IRF8 beyond myeloid lineages.","evidence":"Cell-intrinsic KO, STAT4 requirement, epigenetic profiling, and MCMV infection","pmids":["29858012"],"confidence":"High","gaps":["Direct NK-specific IRF8 target genome not fully cataloged"]},{"year":2019,"claim":"CRISPR enhancer deletion and single-cell genomics established a dose- and enhancer-dependent code (+56-kb, +41-kb, +32-kb; Nfil3-Zeb2-Id2 circuit) that times Irf8 expression to specify versus maintain cDC1 identity.","evidence":"CRISPR enhancer deletion, ATAC-seq, scRNA-seq, genetic epistasis, and conditional deletion in committed cDC1","pmids":["31406378","31406377","41","35830859","33603226"],"confidence":"High","gaps":["Trans-factors reading each enhancer not all identified","How IRF8 dose is sensed at target promoters unresolved"]},{"year":2021,"claim":"Identifying ZMYND8-BRD4 activation of IRF8 enhancers and an IRF8-MEF2D circuit revealed how IRF8 is co-opted as an AML dependency, connecting enhancer regulation to leukemic survival.","evidence":"ChIP-seq, protein interaction mapping, and in vitro/in vivo ZMYND8 knockout","pmids":["34358447"],"confidence":"High","gaps":["Therapeutic tractability of the circuit not addressed in this synthesis"]},{"year":2022,"claim":"The discovery that Ser151-phosphorylated IRF8 binds STING to promote its polymerization revealed a transcription-independent role in cGAS-STING/TBK1 innate immune signaling.","evidence":"Phospho-mutant analysis, co-IP, STING polymerization assays, and HSV-1 infection of IRF8-deficient monocytes","pmids":["35973990"],"confidence":"High","gaps":["Kinase responsible for Ser151 phosphorylation not identified here","Interplay between transcriptional and non-transcriptional roles unresolved"]},{"year":2024,"claim":"Multi-omic epigenomic profiling showed IRF8 stepwise establishes microglial enhancer accessibility and DNA methylation with Sall1 and PU.1, and is continuously required to maintain microglial identity versus disease-associated states.","evidence":"ChIP-seq, ATAC-seq, scRNA/scATAC-seq, bisulfite sequencing, and conditional deletion in the 5xFAD model","pmids":["39313544","30484118"],"confidence":"High","gaps":["Mechanism coupling IRF8 binding to DNA methylation changes not defined","Relevance to human microglial disease not directly tested"]},{"year":2022,"claim":"Cell-type-specific deletion and post-transcriptional regulation studies placed IRF8 at the interface of tumor immunity—TAM IRF8 drives CTL exhaustion, while FTO/m6A and miR-22 tune IRF8 levels to control differentiation and malignancy.","evidence":"TAM-specific and tumor conditional KO, antigen presentation/exhaustion assays, m6A-seq, RIP-seq, and luciferase 3'UTR reporters","pmids":["36288724","36478193","23251709","32735845"],"confidence":"High","gaps":["Context-dependent pro- versus anti-tumor roles of IRF8 not fully reconciled","Some post-transcriptional mechanisms single-lab"]},{"year":null,"claim":"How IRF8's transcriptional and non-transcriptional (STING) activities are coordinated within a single cell, and what upstream kinases and dose-sensing mechanisms integrate the diverse signaling inputs into context-specific enhancer choice, remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unified model linking Ser151/Tyr phosphorylation events to transcriptional output","Kinase(s) and full PTM code not defined","Determinants of activator-versus-repressor partner selection incompletely mapped"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[2,4,5,9,19,34,41,46]},{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[2,17,18,19,49]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[43]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[2,9,19]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[43]}],"pathway":[{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[5,7,34,35,47]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[1,2,19,41]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[4,25,37,41,46]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[6,16,40,44]},{"term_id":"R-HSA-9612973","term_label":"Autophagy","supporting_discovery_ids":[30]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[43,48]},{"term_id":"R-HSA-4839726","term_label":"Chromatin organization","supporting_discovery_ids":[46,37,41]}],"complexes":[],"partners":["PU.1","IRF1","IRF2","IRF3","IRF4","BATF","NFATC1","STING1"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q02556","full_name":"Interferon regulatory factor 8","aliases":["Interferon consensus sequence-binding protein","H-ICSBP","ICSBP"],"length_aa":426,"mass_kda":48.4,"function":"Transcription factor that specifically binds to the upstream regulatory region of type I interferon (IFN) and IFN-inducible MHC class I genes (the interferon consensus sequence (ICS)) (PubMed:25122610). Can both act as a transcriptional activator or repressor (By similarity). Plays a negative regulatory role in cells of the immune system (By similarity). Involved in CD8(+) dendritic cell differentiation by forming a complex with the BATF-JUNB heterodimer in immune cells, leading to recognition of AICE sequence (5'-TGAnTCA/GAAA-3'), an immune-specific regulatory element, followed by cooperative binding of BATF and IRF8 and activation of genes (By similarity). Required for the development of plasmacytoid dendritic cells (pDCs), which produce most of the type I IFN in response to viral infection (By similarity). Positively regulates macroautophagy in dendritic cells (PubMed:29434592). Acts as a transcriptional repressor of osteoclast differentiation factors such as NFATC1 and EEIG1 (By similarity)","subcellular_location":"Nucleus; Cytoplasm","url":"https://www.uniprot.org/uniprotkb/Q02556/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/IRF8","classification":"Not Classified","n_dependent_lines":16,"n_total_lines":1208,"dependency_fraction":0.013245033112582781},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/IRF8","total_profiled":1310},"omim":[{"mim_id":"614983","title":"BASIC LEUCINE ZIPPER TRANSCRIPTION FACTOR, ATF-LIKE 2; BATF2","url":"https://www.omim.org/entry/614983"},{"mim_id":"614893","title":"IMMUNODEFICIENCY 32A; IMD32A","url":"https://www.omim.org/entry/614893"},{"mim_id":"614810","title":"MULTIPLE SCLEROSIS, SUSCEPTIBILITY TO, 5; MS5","url":"https://www.omim.org/entry/614810"},{"mim_id":"612476","title":"BASIC LEUCINE ZIPPER TRANSCRIPTION FACTOR, ATF-LIKE; BATF","url":"https://www.omim.org/entry/612476"},{"mim_id":"612470","title":"BASIC LEUCINE ZIPPER TRANSCRIPTION FACTOR, ATF-LIKE 3; BATF3","url":"https://www.omim.org/entry/612470"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Enhanced","locations":[{"location":"Nucleoplasm","reliability":"Enhanced"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"lymphoid tissue","ntpm":195.7}],"url":"https://www.proteinatlas.org/search/IRF8"},"hgnc":{"alias_symbol":["IRF-8","ICSBP"],"prev_symbol":["ICSBP1"]},"alphafold":{"accession":"Q02556","domains":[{"cath_id":"1.10.10.10","chopping":"6-118","consensus_level":"high","plddt":90.8209,"start":6,"end":118},{"cath_id":"2.60.200.10","chopping":"201-384","consensus_level":"high","plddt":89.6046,"start":201,"end":384}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q02556","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q02556-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q02556-F1-predicted_aligned_error_v6.png","plddt_mean":74.69},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=IRF8","jax_strain_url":"https://www.jax.org/strain/search?query=IRF8"},"sequence":{"accession":"Q02556","fasta_url":"https://rest.uniprot.org/uniprotkb/Q02556.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q02556/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q02556"}},"corpus_meta":[{"pmid":"8861914","id":"PMC_8861914","title":"Immunodeficiency and chronic myelogenous leukemia-like syndrome in mice with a targeted mutation of the ICSBP gene.","date":"1996","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/8861914","citation_count":563,"is_preprint":false},{"pmid":"21524210","id":"PMC_21524210","title":"IRF8 mutations and human dendritic-cell immunodeficiency.","date":"2011","source":"The New England journal of medicine","url":"https://pubmed.ncbi.nlm.nih.gov/21524210","citation_count":470,"is_preprint":false},{"pmid":"12461077","id":"PMC_12461077","title":"ICSBP is essential for the development of mouse type I interferon-producing cells and for the generation and activation of CD8alpha(+) dendritic cells.","date":"2002","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/12461077","citation_count":337,"is_preprint":false},{"pmid":"24091328","id":"PMC_24091328","title":"Myeloid-derived suppressor cell development is regulated by a STAT/IRF-8 axis.","date":"2013","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/24091328","citation_count":288,"is_preprint":false},{"pmid":"10981959","id":"PMC_10981959","title":"ICSBP directs bipotential myeloid progenitor cells to differentiate into mature macrophages.","date":"2000","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/10981959","citation_count":254,"is_preprint":false},{"pmid":"12393690","id":"PMC_12393690","title":"Essential role for ICSBP in the in vivo development of murine CD8alpha + dendritic cells.","date":"2002","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/12393690","citation_count":252,"is_preprint":false},{"pmid":"32735845","id":"PMC_32735845","title":"Differential IRF8 Transcription Factor Requirement Defines Two Pathways of Dendritic Cell Development in Humans.","date":"2020","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/32735845","citation_count":201,"is_preprint":false},{"pmid":"29593283","id":"PMC_29593283","title":"Breast and pancreatic cancer interrupt IRF8-dependent dendritic cell development to overcome immune surveillance.","date":"2018","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/29593283","citation_count":190,"is_preprint":false},{"pmid":"8321202","id":"PMC_8321202","title":"The genomic structure of the murine ICSBP gene reveals the presence of the gamma interferon-responsive element, to which an ISGF3 alpha subunit (or similar) molecule binds.","date":"1993","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/8321202","citation_count":185,"is_preprint":false},{"pmid":"9414265","id":"PMC_9414265","title":"Lack of interferon consensus sequence binding protein (ICSBP) transcripts in human myeloid leukemias.","date":"1998","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/9414265","citation_count":171,"is_preprint":false},{"pmid":"11846985","id":"PMC_11846985","title":"ICSBP/IRF-8: its regulatory roles in the development of myeloid cells.","date":"2002","source":"Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research","url":"https://pubmed.ncbi.nlm.nih.gov/11846985","citation_count":164,"is_preprint":false},{"pmid":"36288724","id":"PMC_36288724","title":"Tumor-associated macrophages expressing the transcription factor IRF8 promote T cell exhaustion in cancer.","date":"2022","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/36288724","citation_count":161,"is_preprint":false},{"pmid":"29576451","id":"PMC_29576451","title":"IRF8 Regulates Transcription of Naips for NLRC4 Inflammasome Activation.","date":"2018","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/29576451","citation_count":160,"is_preprint":false},{"pmid":"31406378","id":"PMC_31406378","title":"Cryptic activation of an Irf8 enhancer governs cDC1 fate specification.","date":"2019","source":"Nature immunology","url":"https://pubmed.ncbi.nlm.nih.gov/31406378","citation_count":154,"is_preprint":false},{"pmid":"10861061","id":"PMC_10861061","title":"An IFN-gamma-inducible transcription factor, IFN consensus sequence binding protein (ICSBP), stimulates IL-12 p40 expression in macrophages.","date":"2000","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/10861061","citation_count":151,"is_preprint":false},{"pmid":"17687331","id":"PMC_17687331","title":"An IRF8-binding promoter variant and AIRE control CHRNA1 promiscuous expression in thymus.","date":"2007","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/17687331","citation_count":148,"is_preprint":false},{"pmid":"18055870","id":"PMC_18055870","title":"The BXH2 mutation in IRF8 differentially impairs dendritic cell subset development in the mouse.","date":"2007","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/18055870","citation_count":140,"is_preprint":false},{"pmid":"22238324","id":"PMC_22238324","title":"IRF-8 extinguishes neutrophil production and promotes dendritic cell lineage commitment in both myeloid and lymphoid mouse progenitors.","date":"2012","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/22238324","citation_count":123,"is_preprint":false},{"pmid":"25288399","id":"PMC_25288399","title":"The transcription factors IRF8 and PU.1 negatively regulate plasma cell differentiation.","date":"2014","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/25288399","citation_count":122,"is_preprint":false},{"pmid":"18799728","id":"PMC_18799728","title":"IRF8 regulates B-cell lineage specification, commitment, and differentiation.","date":"2008","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/18799728","citation_count":120,"is_preprint":false},{"pmid":"10648600","id":"PMC_10648600","title":"Expression of interferon consensus sequence binding protein (ICSBP) is downregulated in Bcr-Abl-induced murine chronic myelogenous leukemia-like disease, and forced coexpression of ICSBP inhibits Bcr-Abl-induced myeloproliferative disorder.","date":"2000","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/10648600","citation_count":116,"is_preprint":false},{"pmid":"29858012","id":"PMC_29858012","title":"Transcription Factor IRF8 Orchestrates the Adaptive Natural Killer Cell Response.","date":"2018","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/29858012","citation_count":108,"is_preprint":false},{"pmid":"18806934","id":"PMC_18806934","title":"IRF8 regulates myeloid and B lymphoid lineage diversification.","date":"2009","source":"Immunologic research","url":"https://pubmed.ncbi.nlm.nih.gov/18806934","citation_count":105,"is_preprint":false},{"pmid":"25749660","id":"PMC_25749660","title":"Regulation of myelopoiesis by the transcription factor IRF8.","date":"2015","source":"International journal of hematology","url":"https://pubmed.ncbi.nlm.nih.gov/25749660","citation_count":102,"is_preprint":false},{"pmid":"7768900","id":"PMC_7768900","title":"Functional domain analysis of interferon consensus sequence binding protein (ICSBP) and its association with interferon regulatory factors.","date":"1995","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/7768900","citation_count":99,"is_preprint":false},{"pmid":"31406377","id":"PMC_31406377","title":"An Nfil3-Zeb2-Id2 pathway imposes Irf8 enhancer switching during cDC1 development.","date":"2019","source":"Nature immunology","url":"https://pubmed.ncbi.nlm.nih.gov/31406377","citation_count":97,"is_preprint":false},{"pmid":"32232558","id":"PMC_32232558","title":"Role of IRF8 in immune cells functions, protection against infections, and susceptibility to inflammatory diseases.","date":"2020","source":"Human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/32232558","citation_count":94,"is_preprint":false},{"pmid":"12393459","id":"PMC_12393459","title":"ICSBP/IRF-8 retrovirus transduction rescues dendritic cell development in vitro.","date":"2002","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/12393459","citation_count":93,"is_preprint":false},{"pmid":"27893462","id":"PMC_27893462","title":"Biallelic mutations in IRF8 impair human NK cell maturation and function.","date":"2016","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/27893462","citation_count":88,"is_preprint":false},{"pmid":"15781580","id":"PMC_15781580","title":"A mutation in the Icsbp1 gene causes susceptibility to infection and a chronic myeloid leukemia-like syndrome in BXH-2 mice.","date":"2005","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/15781580","citation_count":86,"is_preprint":false},{"pmid":"14615368","id":"PMC_14615368","title":"ICSBP is critically involved in the normal development and trafficking of Langerhans cells and dermal dendritic cells.","date":"2003","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/14615368","citation_count":85,"is_preprint":false},{"pmid":"12876285","id":"PMC_12876285","title":"Activation of the murine interleukin-12 p40 promoter by functional interactions between NFAT and ICSBP.","date":"2003","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12876285","citation_count":82,"is_preprint":false},{"pmid":"22003407","id":"PMC_22003407","title":"Shared and distinct functions of the transcription factors IRF4 and IRF8 in myeloid cell development.","date":"2011","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/22003407","citation_count":82,"is_preprint":false},{"pmid":"14656881","id":"PMC_14656881","title":"Interferon consensus sequence binding protein (ICSBP; IRF-8) antagonizes BCR/ABL and down-regulates bcl-2.","date":"2003","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/14656881","citation_count":78,"is_preprint":false},{"pmid":"31000603","id":"PMC_31000603","title":"Transcription factors IRF8 and PU.1 are required for follicular B cell development and BCL6-driven germinal center responses.","date":"2019","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/31000603","citation_count":71,"is_preprint":false},{"pmid":"12417340","id":"PMC_12417340","title":"IRF-8/ICSBP and IRF-1 cooperatively stimulate mouse IL-12 promoter activity in macrophages.","date":"2002","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/12417340","citation_count":69,"is_preprint":false},{"pmid":"16597464","id":"PMC_16597464","title":"Identification of IRF-8 and IRF-1 target genes in activated macrophages.","date":"2006","source":"Molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/16597464","citation_count":68,"is_preprint":false},{"pmid":"30484118","id":"PMC_30484118","title":"Transcriptional mechanism of IRF8 and PU.1 governs microglial activation in neurodegenerative condition.","date":"2018","source":"Protein & cell","url":"https://pubmed.ncbi.nlm.nih.gov/30484118","citation_count":67,"is_preprint":false},{"pmid":"25775030","id":"PMC_25775030","title":"IRF8 directs stress-induced autophagy in macrophages and promotes clearance of Listeria monocytogenes.","date":"2015","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/25775030","citation_count":67,"is_preprint":false},{"pmid":"21228327","id":"PMC_21228327","title":"IRF8 and IRF3 cooperatively regulate rapid interferon-β induction in human blood monocytes.","date":"2011","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/21228327","citation_count":67,"is_preprint":false},{"pmid":"11846986","id":"PMC_11846986","title":"ICSBP/IRF-8 transactivation: a tale of protein-protein interaction.","date":"2002","source":"Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research","url":"https://pubmed.ncbi.nlm.nih.gov/11846986","citation_count":66,"is_preprint":false},{"pmid":"12370291","id":"PMC_12370291","title":"Gamma interferon triggers interaction between ICSBP (IRF-8) and TEL, recruiting the histone deacetylase HDAC3 to the interferon-responsive element.","date":"2002","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/12370291","citation_count":61,"is_preprint":false},{"pmid":"21487040","id":"PMC_21487040","title":"IRF8 regulates acid ceramidase expression to mediate apoptosis and suppresses myelogeneous leukemia.","date":"2011","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/21487040","citation_count":61,"is_preprint":false},{"pmid":"28090699","id":"PMC_28090699","title":"Modelling IRF8 Deficient Human Hematopoiesis and Dendritic Cell Development with Engineered iPS Cells.","date":"2017","source":"Stem cells (Dayton, Ohio)","url":"https://pubmed.ncbi.nlm.nih.gov/28090699","citation_count":58,"is_preprint":false},{"pmid":"11823414","id":"PMC_11823414","title":"Disabled-2 is transcriptionally regulated by ICSBP and augments macrophage spreading and adhesion.","date":"2002","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/11823414","citation_count":56,"is_preprint":false},{"pmid":"29233972","id":"PMC_29233972","title":"IRF8-dependent molecular complexes control the Th9 transcriptional program.","date":"2017","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/29233972","citation_count":55,"is_preprint":false},{"pmid":"34358447","id":"PMC_34358447","title":"ZMYND8-regulated IRF8 transcription axis is an acute myeloid leukemia dependency.","date":"2021","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/34358447","citation_count":54,"is_preprint":false},{"pmid":"12933588","id":"PMC_12933588","title":"ICSBP/IRF-8 inhibits mitogenic activity of p210 Bcr/Abl in differentiating myeloid progenitor cells.","date":"2003","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/12933588","citation_count":53,"is_preprint":false},{"pmid":"33603226","id":"PMC_33603226","title":"A RUNX-CBFβ-driven enhancer directs the Irf8 dose-dependent lineage choice between DCs and monocytes.","date":"2021","source":"Nature immunology","url":"https://pubmed.ncbi.nlm.nih.gov/33603226","citation_count":53,"is_preprint":false},{"pmid":"18195016","id":"PMC_18195016","title":"The interferon consensus sequence-binding protein (ICSBP/IRF8) represses PTPN13 gene transcription in differentiating myeloid cells.","date":"2008","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/18195016","citation_count":52,"is_preprint":false},{"pmid":"26932576","id":"PMC_26932576","title":"PU.1 cooperates with IRF4 and IRF8 to suppress pre-B-cell leukemia.","date":"2016","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/26932576","citation_count":52,"is_preprint":false},{"pmid":"35830859","id":"PMC_35830859","title":"IRF8 deficiency induces the transcriptional, functional, and epigenetic reprogramming of cDC1 into the cDC2 lineage.","date":"2022","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/35830859","citation_count":52,"is_preprint":false},{"pmid":"17200120","id":"PMC_17200120","title":"PU.1, interferon regulatory factor (IRF) 2, and the interferon consensus sequence-binding protein (ICSBP/IRF8) cooperate to activate NF1 transcription in differentiating myeloid cells.","date":"2007","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/17200120","citation_count":51,"is_preprint":false},{"pmid":"14976051","id":"PMC_14976051","title":"The interferon regulatory factor ICSBP/IRF-8 in combination with PU.1 up-regulates expression of tumor suppressor p15(Ink4b) in murine myeloid cells.","date":"2004","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/14976051","citation_count":50,"is_preprint":false},{"pmid":"32375053","id":"PMC_32375053","title":"Suppression of Inflammasome Activation by IRF8 and IRF4 in cDCs Is Critical for T Cell Priming.","date":"2020","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/32375053","citation_count":50,"is_preprint":false},{"pmid":"36078039","id":"PMC_36078039","title":"IRF8: Mechanism of Action and Health Implications.","date":"2022","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/36078039","citation_count":48,"is_preprint":false},{"pmid":"32373114","id":"PMC_32373114","title":"IRF3 and IRF8 Regulate NF-κB Signaling by Targeting MyD88 in Teleost Fish.","date":"2020","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/32373114","citation_count":47,"is_preprint":false},{"pmid":"31634546","id":"PMC_31634546","title":"Leukocyte-specific siRNA delivery revealing IRF8 as a potential anti-inflammatory target.","date":"2019","source":"Journal of controlled release : official journal of the Controlled Release Society","url":"https://pubmed.ncbi.nlm.nih.gov/31634546","citation_count":46,"is_preprint":false},{"pmid":"23965942","id":"PMC_23965942","title":"Genetic variation near IRF8 is associated with serologic and cytokine profiles in systemic lupus erythematosus and multiple sclerosis.","date":"2013","source":"Genes and immunity","url":"https://pubmed.ncbi.nlm.nih.gov/23965942","citation_count":45,"is_preprint":false},{"pmid":"24101380","id":"PMC_24101380","title":"Cross talk between Wnt/β-catenin and Irf8 in leukemia progression and drug resistance.","date":"2013","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/24101380","citation_count":45,"is_preprint":false},{"pmid":"20679491","id":"PMC_20679491","title":"Interferon consensus sequence binding protein (ICSBP) decreases beta-catenin activity in myeloid cells by repressing GAS2 transcription.","date":"2010","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/20679491","citation_count":44,"is_preprint":false},{"pmid":"32199911","id":"PMC_32199911","title":"CD163 expression defines specific, IRF8-dependent, immune-modulatory macrophages in the bone marrow.","date":"2020","source":"The Journal of allergy and clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/32199911","citation_count":44,"is_preprint":false},{"pmid":"25506356","id":"PMC_25506356","title":"IRF4 and IRF8: Governing the virtues of B Lymphocytes.","date":"2014","source":"Frontiers in biology","url":"https://pubmed.ncbi.nlm.nih.gov/25506356","citation_count":44,"is_preprint":false},{"pmid":"35973990","id":"PMC_35973990","title":"Transcription-independent regulation of STING activation and innate immune responses by IRF8 in monocytes.","date":"2022","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/35973990","citation_count":44,"is_preprint":false},{"pmid":"16462767","id":"PMC_16462767","title":"Interferon-gamma induces regression of epithelial cell carcinoma: critical roles of IRF-1 and ICSBP transcription factors.","date":"2006","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/16462767","citation_count":43,"is_preprint":false},{"pmid":"7526889","id":"PMC_7526889","title":"IFN consensus sequence binding protein (ICSBP) is a conditional repressor of IFN inducible promoters.","date":"1994","source":"International immunology","url":"https://pubmed.ncbi.nlm.nih.gov/7526889","citation_count":42,"is_preprint":false},{"pmid":"17675508","id":"PMC_17675508","title":"Icsbp1/IRF-8 is required for innate and adaptive immune responses against intracellular pathogens.","date":"2007","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/17675508","citation_count":41,"is_preprint":false},{"pmid":"26166768","id":"PMC_26166768","title":"Transcription factor IRF8 controls Th1-like regulatory T-cell function.","date":"2015","source":"Cellular & molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/26166768","citation_count":40,"is_preprint":false},{"pmid":"7536924","id":"PMC_7536924","title":"Chicken interferon consensus sequence-binding protein (ICSBP) and interferon regulatory factor (IRF) 1 genes reveal evolutionary conservation in the IRF gene family.","date":"1995","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/7536924","citation_count":38,"is_preprint":false},{"pmid":"18802108","id":"PMC_18802108","title":"IFN consensus sequence binding protein (Icsbp) is critical for eosinophil development.","date":"2008","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/18802108","citation_count":37,"is_preprint":false},{"pmid":"26606328","id":"PMC_26606328","title":"STAT1 and IRF8 in Vascular Inflammation and Cardiovascular Disease: Diagnostic and Therapeutic Potential.","date":"2015","source":"International reviews of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/26606328","citation_count":36,"is_preprint":false},{"pmid":"18922617","id":"PMC_18922617","title":"Epigenetic silencing of the interferon regulatory factor ICSBP/IRF8 in human multiple myeloma.","date":"2008","source":"Experimental hematology","url":"https://pubmed.ncbi.nlm.nih.gov/18922617","citation_count":35,"is_preprint":false},{"pmid":"18580679","id":"PMC_18580679","title":"Expression of the interferon regulatory factor 8/ICSBP-1 in human reactive lymphoid tissues and B-cell lymphomas: a novel germinal center marker.","date":"2008","source":"The American journal of surgical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/18580679","citation_count":35,"is_preprint":false},{"pmid":"28008797","id":"PMC_28008797","title":"IRF8 is the target of SIRT1 for the inflammation response in macrophages.","date":"2016","source":"Innate immunity","url":"https://pubmed.ncbi.nlm.nih.gov/28008797","citation_count":33,"is_preprint":false},{"pmid":"23251709","id":"PMC_23251709","title":"miR-22 controls Irf8 mRNA abundance and murine dendritic cell development.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23251709","citation_count":32,"is_preprint":false},{"pmid":"20585039","id":"PMC_20585039","title":"Cooperation between deficiencies of IRF-4 and IRF-8 promotes both myeloid and lymphoid tumorigenesis.","date":"2010","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/20585039","citation_count":32,"is_preprint":false},{"pmid":"33535228","id":"PMC_33535228","title":"Brd4 regulates NLRC4 inflammasome activation by facilitating IRF8-mediated transcription of Naips.","date":"2021","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/33535228","citation_count":32,"is_preprint":false},{"pmid":"24832596","id":"PMC_24832596","title":"Interferon consensus sequence-binding protein (ICSBP) promotes epithelial-to-mesenchymal transition (EMT)-like phenomena, cell-motility, and invasion via TGF-β signaling in U2OS cells.","date":"2014","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/24832596","citation_count":31,"is_preprint":false},{"pmid":"35388006","id":"PMC_35388006","title":"Lupus enhancer risk variant causes dysregulation of IRF8 through cooperative lncRNA and DNA methylation machinery.","date":"2022","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/35388006","citation_count":31,"is_preprint":false},{"pmid":"24227775","id":"PMC_24227775","title":"Batf3 and Id2 have a synergistic effect on Irf8-directed classical CD8α+ dendritic cell development.","date":"2013","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/24227775","citation_count":31,"is_preprint":false},{"pmid":"32205422","id":"PMC_32205422","title":"IRF8 Regulates Gram-Negative Bacteria-Mediated NLRP3 Inflammasome Activation and Cell Death.","date":"2020","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/32205422","citation_count":30,"is_preprint":false},{"pmid":"30840779","id":"PMC_30840779","title":"Inactivating Mutation in IRF8 Promotes Osteoclast Transcriptional Programs and Increases Susceptibility to Tooth Root Resorption.","date":"2019","source":"Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research","url":"https://pubmed.ncbi.nlm.nih.gov/30840779","citation_count":30,"is_preprint":false},{"pmid":"39313544","id":"PMC_39313544","title":"IRF8 defines the epigenetic landscape in postnatal microglia, thereby directing their transcriptome programs.","date":"2024","source":"Nature immunology","url":"https://pubmed.ncbi.nlm.nih.gov/39313544","citation_count":29,"is_preprint":false},{"pmid":"35525407","id":"PMC_35525407","title":"IL-10 inhibits osteoclast differentiation and osteolysis through MEG3/IRF8 pathway.","date":"2022","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/35525407","citation_count":28,"is_preprint":false},{"pmid":"10102295","id":"PMC_10102295","title":"Interferon-gamma signaling in human retinal pigment epithelial cells mediated by STAT1, ICSBP, and IRF-1 transcription factors.","date":"1999","source":"Investigative ophthalmology & visual science","url":"https://pubmed.ncbi.nlm.nih.gov/10102295","citation_count":26,"is_preprint":false},{"pmid":"19171873","id":"PMC_19171873","title":"ICSBP-mediated immune protection against BCR-ABL-induced leukemia requires the CCL6 and CCL9 chemokines.","date":"2009","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/19171873","citation_count":25,"is_preprint":false},{"pmid":"22082370","id":"PMC_22082370","title":"Feedback inhibition of osteoclastogenesis during inflammation by IL-10, M-CSF receptor shedding, and induction of IRF8.","date":"2011","source":"Annals of the New York Academy of Sciences","url":"https://pubmed.ncbi.nlm.nih.gov/22082370","citation_count":25,"is_preprint":false},{"pmid":"24957708","id":"PMC_24957708","title":"Constitutive IRF8 expression inhibits AML by activation of repressed immune response signaling.","date":"2014","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/24957708","citation_count":25,"is_preprint":false},{"pmid":"35293774","id":"PMC_35293774","title":"Host Cells Actively Resist Porcine Reproductive and Respiratory Syndrome Virus Infection via the IRF8-MicroRNA-10a-SRP14 Regulatory Pathway.","date":"2022","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/35293774","citation_count":24,"is_preprint":false},{"pmid":"23828296","id":"PMC_23828296","title":"IRF5, IRF8, and IRF7 in human pDCs - the good, the bad, and the insignificant?","date":"2013","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/23828296","citation_count":24,"is_preprint":false},{"pmid":"34282122","id":"PMC_34282122","title":"IRF-8/miR-451a regulates M-MDSC differentiation via the AMPK/mTOR signal pathway during lupus development.","date":"2021","source":"Cell death discovery","url":"https://pubmed.ncbi.nlm.nih.gov/34282122","citation_count":23,"is_preprint":false},{"pmid":"33766090","id":"PMC_33766090","title":"High IRF8 expression correlates with CD8 T cell infiltration and is a predictive biomarker of therapy response in ER-negative breast cancer.","date":"2021","source":"Breast cancer research : BCR","url":"https://pubmed.ncbi.nlm.nih.gov/33766090","citation_count":23,"is_preprint":false},{"pmid":"36478193","id":"PMC_36478193","title":"Silencing of IRF8 Mediated by m6A Modification Promotes the Progression of T-Cell Acute Lymphoblastic Leukemia.","date":"2022","source":"Advanced science (Weinheim, Baden-Wurttemberg, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/36478193","citation_count":23,"is_preprint":false},{"pmid":"16569763","id":"PMC_16569763","title":"ICSBP/IRF-8 differentially regulates antigen uptake during dendritic-cell development and affects antigen presentation to CD4+ T cells.","date":"2006","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/16569763","citation_count":22,"is_preprint":false},{"pmid":"33897697","id":"PMC_33897697","title":"PU.1 and IRF8 Modulate Activation of NLRP3 Inflammasome via Regulating Its Expression in Human Macrophages.","date":"2021","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/33897697","citation_count":22,"is_preprint":false},{"pmid":"18596738","id":"PMC_18596738","title":"Decreased IRF8 expression found in aging hematopoietic progenitor/stem cells.","date":"2008","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/18596738","citation_count":22,"is_preprint":false},{"pmid":"26683374","id":"PMC_26683374","title":"The Interferon Consensus Sequence Binding Protein (Icsbp/Irf8) Is Required for Termination of Emergency Granulopoiesis.","date":"2015","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/26683374","citation_count":20,"is_preprint":false},{"pmid":"25989711","id":"PMC_25989711","title":"Association of IRF8 gene polymorphisms with autoimmune thyroid disease.","date":"2015","source":"European journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/25989711","citation_count":20,"is_preprint":false},{"pmid":"28856571","id":"PMC_28856571","title":"IRF-8 is Involved in Amyloid-β1-40 (Aβ1-40)-induced Microglial Activation: a New Implication in Alzheimer's Disease.","date":"2017","source":"Journal of molecular neuroscience : MN","url":"https://pubmed.ncbi.nlm.nih.gov/28856571","citation_count":19,"is_preprint":false},{"pmid":"24218455","id":"PMC_24218455","title":"A role for IRF8 in B cell anergy.","date":"2013","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/24218455","citation_count":19,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":49508,"output_tokens":12088,"usd":0.164922,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":23251,"output_tokens":6101,"usd":0.13439,"stage2_stop_reason":"end_turn"},"total_usd":0.299312,"stage1_batch_id":"msgbatch_01DUPACZi7AAWwuZiUjseQF4","stage2_batch_id":"msgbatch_018yt7chE3f48PEFtDwtj6AE","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1996,\n      \"finding\": \"Targeted null mutation of ICSBP (IRF8) in mice causes immunodeficiency with impaired IFN-γ production and a CML-like myeloproliferative syndrome progressing to fatal blast crisis, establishing IRF8 as a regulator of hematopoietic progenitor cell proliferation and differentiation.\",\n      \"method\": \"Gene knockout mouse model (ICSBP-/- mice), bone marrow transfer, phenotypic analysis\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — clean KO with defined cellular phenotypes, replicated and foundational study widely cited\",\n      \"pmids\": [\"8861914\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"The murine ICSBP gene contains a palindromic IFN response element (pIRE, TTCNNGGAA) in its promoter that confers IFN-γ induction via binding of the 91-kDa ISGF3α subunit (STAT1), establishing ICSBP as an IFN-γ-inducible gene regulated by STAT1.\",\n      \"method\": \"Gel mobility shift assay, heterologous promoter reporter assay, antibody supershift\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro binding assay with mutagenesis and reporter validation, foundational mechanistic study\",\n      \"pmids\": [\"8321202\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"ICSBP contains at least three independent functional domains: a DNA-binding domain (DBD, aa 1-121), a transcriptional repressor domain, and an IRF-association domain (IAD) that mediates protein-protein interaction with IRF-1 and IRF-2 in vitro and in vivo.\",\n      \"method\": \"Domain deletion mutagenesis, VP16/GAL4 fusion constructs, electrophoretic mobility shift assay (EMSA), co-IP\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro reconstitution with mutagenesis and multiple orthogonal methods\",\n      \"pmids\": [\"7768900\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"ICSBP acts as a conditional repressor of IFN-stimulated response element (ISRE)-containing promoters in hematopoietic cells; IRF-1 competes with ICSBP for ISRE binding and alleviates ICSBP-mediated repression, revealing a balance between positive (IRF-1) and negative (ICSBP) regulators of ISG expression.\",\n      \"method\": \"Reporter gene assay, EMSA competition assay\",\n      \"journal\": \"International immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Weak — functional reporter and EMSA in single study, single lab\",\n      \"pmids\": [\"7526889\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"ICSBP drives myeloid progenitor differentiation toward mature macrophages and represses granulocyte-specific genes; retroviral transduction of ICSBP into ICSBP-/- myeloid progenitors induced growth arrest, macrophage-specific gene expression, phagocytic activity, and inhibited G-CSF-mediated granulocytic differentiation.\",\n      \"method\": \"Retroviral transduction, in vitro differentiation assay, target DNA binding assay\",\n      \"journal\": \"Immunity\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — loss-of-function rescue with retroviral expression, specific phenotypic readouts, replicated in multiple studies\",\n      \"pmids\": [\"10981959\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"ICSBP (IRF8) is required for IL-12 p40 transcription in macrophages; it acts as a principal transcriptional activator of the IL-12 p40 promoter through the Ets binding site via protein-protein interaction, and synergizes with IRF-1. ICSBP-/- macrophage-like cells fail to induce IL-12 p40 after IFN-γ/LPS stimulation.\",\n      \"method\": \"Reporter gene assay, DNA affinity binding assay, endogenous mRNA induction, ICSBP-/- cell lines\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — multiple orthogonal methods, loss-of-function and gain-of-function, replicated across multiple studies\",\n      \"pmids\": [\"10861061\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"ICSBP expression is downregulated by BCR-ABL in CML, and forced co-expression of ICSBP inhibits BCR-ABL-induced colony formation and CML-like disease in vivo, establishing ICSBP as a tumor suppressor that counteracts BCR-ABL-driven myeloproliferation.\",\n      \"method\": \"Retroviral transduction, colony formation assay, murine bone marrow transplantation model\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo murine CML model with both in vitro and in vivo readouts\",\n      \"pmids\": [\"10648600\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"ICSBP is required for development of CD8α+ dendritic cells and mouse IFN-producing cells (plasmacytoid DC precursors) in vivo; ICSBP-/- mice lack CD8α+ DCs selectively, and this defect is intrinsic to bone marrow-derived progenitors.\",\n      \"method\": \"ICSBP-/- mouse analysis, bone marrow chimera experiments, flow cytometry, RT-PCR\",\n      \"journal\": \"The Journal of experimental medicine / Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — two independent groups (PMIDs 12461077 and 12393690) using KO mice and chimeras, replicated\",\n      \"pmids\": [\"12461077\", \"12393690\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"ICSBP's transcriptional function—requiring intact DNA-binding activity and ability to interact with partner proteins (PU.1 and other IRFs)—is essential for DC development and maturation; ICSBP mutants lacking either activity fail to rescue DC development from ICSBP-/- bone marrow.\",\n      \"method\": \"Retroviral transduction of ICSBP mutants into ICSBP-/- bone marrow, in vitro DC differentiation with Flt3 ligand\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — structure-function mutagenesis with defined rescue readout, single lab\",\n      \"pmids\": [\"12393459\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Upon IFN-γ stimulation, ICSBP interacts with the Ets protein TEL at the ISRE, recruiting histone deacetylase HDAC3 to the element, causing repression of ISRE-dependent transcription as a negative-feedback mechanism; this is distinct from ICSBP-PU.1 interactions at the EICE.\",\n      \"method\": \"Mass spectrometry of ISRE-bound proteins, in vitro binding with recombinant proteins, reporter assay, co-IP\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — mass spectrometry identification plus in vitro reconstitution with recombinant proteins and reporter assay\",\n      \"pmids\": [\"12370291\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"ICSBP and IRF-1 cooperatively stimulate murine IL-12 p40 promoter activity through a novel ISRE-like cis element (distinct from the Ets and NF-κB sites); mutation of this element abrogates ICSBP/IRF-1-driven activation.\",\n      \"method\": \"Reporter gene assay with promoter mutations, co-transfection in RAW 264.7 macrophages\",\n      \"journal\": \"FEBS letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Weak — functional reporter with mutagenesis, single lab\",\n      \"pmids\": [\"12417340\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"NFAT physically associates with ICSBP in the absence of DNA (co-IP of endogenous proteins) and is required for ICSBP binding to the IL-12 p40 promoter; NFAT and ICSBP synergistically activate the p40 promoter, and this interaction is abrogated by IL-10.\",\n      \"method\": \"Co-immunoprecipitation of endogenous proteins, ChIP, reporter gene assay, dominant negative NFAT\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal Co-IP of endogenous proteins plus ChIP and functional reporter, single lab\",\n      \"pmids\": [\"12876285\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"ICSBP inhibits growth of BCR/ABL-transformed myeloid progenitor cells by transcriptionally repressing c-Myc indirectly through direct activation of Blimp-1 and METS/PE1 (potent c-Myc repressors), without affecting BCR/ABL kinase activity.\",\n      \"method\": \"Conditional ICSBP/ER chimera expression, mRNA expression analysis, ectopic Blimp-1 expression\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — conditional expression system with mechanistic dissection, single lab\",\n      \"pmids\": [\"12933588\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"ICSBP antagonizes BCR/ABL and represses bcl-2 transcription via two ICSBP-responsive elements in the bcl-2 promoter, as shown by reporter gene assays and EMSA; ICSBP overcomes BCR/ABL-induced morphology changes, chemotherapy resistance, and repression of differentiation.\",\n      \"method\": \"Reporter gene assay, EMSA, stable/conditional ICSBP expression in BCR/ABL-transformed cells\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — reporter and EMSA plus functional in vivo model, single lab\",\n      \"pmids\": [\"14656881\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"ICSBP is critically required for development and trafficking of Langerhans cells and dermal DCs; ICSBP-/- DCs show reduced CCR6 and CCR7 expression, impaired migratory response to MIP-3α, MIP-3β, and CCL21, and failure to initiate contact hypersensitivity responses.\",\n      \"method\": \"ICSBP-/- mouse analysis, in vitro migration assay, RT-PCR for chemokine receptors, contact hypersensitivity model\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — KO mouse with defined cellular phenotype and mechanistic pathway (chemokine receptor expression), single lab\",\n      \"pmids\": [\"14615368\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"ICSBP/IRF-8 cooperates with PU.1 to activate transcription of the p15(Ink4b) cyclin-dependent kinase inhibitor gene; both ICSBP and PU.1 must bind DNA to form a stable complex at the p15 promoter, providing a mechanism for ICSBP tumor suppressor activity in myeloid cells.\",\n      \"method\": \"Reporter gene assay, EMSA (PU.1/ICSBP binding complex), ICSBP transduction into ICSBP-null cells\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — functional reporter with EMSA and gain-of-function, single lab\",\n      \"pmids\": [\"14976051\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"The BXH-2 mouse carries an R294C substitution in the IRF association domain (IAD) of IRF8/ICSBP; this loss-of-function mutation impairs IL-12 production and causes myeloproliferation and immunodeficiency, confirming the IAD is essential for IRF8 function.\",\n      \"method\": \"Positional cloning, sequencing, transactivation reporter assay in RAW 264.7 macrophages\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — identified causal mutation, confirmed by functional assay, replicated by multiple studies\",\n      \"pmids\": [\"15781580\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"The IRF8 R294C mutation (BXH2) abolishes interaction of IRF8 with partner transcription factors and prevents binding to promoters requiring partner interactions, selectively eliminating CD8α+ DC development and IL-12p40 production while retaining pDC development and type I IFN production.\",\n      \"method\": \"EMSA, chromatin immunoprecipitation (ChIP), flow cytometry of DC subsets in BXH2 mice\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — EMSA plus ChIP plus in vivo phenotyping, mechanistic separation of DC subsets established\",\n      \"pmids\": [\"18055870\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"IRF8 binds to a variant in the CHRNA1 promoter and activates CHRNA1 transcription in thymic epithelial cells; the K108E disease-associated variant prevents IRF8 binding and abrogates promoter activity, demonstrating IRF8 controls thymic promiscuous expression of a self-antigen.\",\n      \"method\": \"Promoter reporter assay in thymic epithelial cells, EMSA, in vitro mutagenesis\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — reporter assay and EMSA in primary and cell line contexts, single lab\",\n      \"pmids\": [\"17687331\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"IRF8 binds directly to IRF8/Ets consensus sequences in the promoters of Sfpi1 (encoding PU.1) and Ebf1, repressing Sfpi1 and activating Ebf1; a signaling-deficient IRF8 mutant fails to rescue B-cell lineage specification from IRF8-/- HSCs.\",\n      \"method\": \"ChIP, reporter gene assay, retroviral transduction of IRF8 mutants into IRF8-/- HSCs\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — ChIP plus functional rescue with mutant, single lab, multiple methods\",\n      \"pmids\": [\"18799728\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"ICSBP represses PTPN13 (Fap-1) transcription via a cis element in its proximal promoter in myeloid cells; this repression is regulated by phosphorylation of conserved tyrosine residues in the IRF domain of ICSBP, and loss of ICSBP increases Fap-1, resulting in Fas dephosphorylation and apoptosis resistance.\",\n      \"method\": \"CpG island microarray ChIP screen, reporter gene assay, phosphorylation mutants, apoptosis assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — ChIP identification followed by reporter and mutagenesis, single lab\",\n      \"pmids\": [\"18195016\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"ICSBP/IRF-8 cooperates with PU.1 and IRF-2 to activate NF1 transcription via a composite ets/IRF cis element; PU.1 binds DNA first, recruits IRF-2 (requiring phosphorylation of specific serine residues in PU.1 PEST domain and an IRF domain tyrosine in IRF-2), and ICSBP then interacts with the DNA-bound PU.1-IRF-2 heterodimer (requiring its own conserved IRF domain tyrosine).\",\n      \"method\": \"EMSA, reporter gene assay, phosphorylation mutant analysis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro binding assay with mutagenesis, functional reporter, single lab\",\n      \"pmids\": [\"17200120\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"ICSBP/IRF8 decreases β-catenin activity in myeloid cells by repressing GAS2 transcription (via ICSBP/Tel/HDAC3 complex at GAS2 promoter); Gas2 inhibits calpain protease, and β-catenin is a calpain substrate, so ICSBP loss elevates Gas2, inhibits calpain, and increases β-catenin protein and activity.\",\n      \"method\": \"ChIP (ICSBP/Tel/HDAC3 at GAS2 promoter), reporter gene assay, calpain activity assay, β-catenin protein quantification\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — ChIP plus biochemical pathway dissection with multiple orthogonal methods, single lab\",\n      \"pmids\": [\"20679491\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"IRF8 regulates acid ceramidase (A-CDase) expression by directly binding to its promoter; loss of IRF8 increases A-CDase protein, leading to reduced C16 ceramide and resistance to FasL-induced apoptosis in CML cells, while restoration of IRF8 suppresses CML via a Fas-dependent mechanism.\",\n      \"method\": \"ChIP (IRF8 binding to A-CDase promoter), reporter assay, ceramide measurement, apoptosis assay, in vivo CML model\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — ChIP plus in vitro and in vivo functional readouts, single lab, multiple methods\",\n      \"pmids\": [\"21487040\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"IRF8 is required for IFN-β induction in human blood monocytes by cooperating with IRF3; IRF8 constitutively binds the EICE of the IFN-β promoter together with PU.1 in vivo, forming a scaffold that facilitates recruitment of IRF3. The protein-protein interaction between IRF8 and IRF3 is independent of both the DBD of IRF8 and the IAD of IRF3.\",\n      \"method\": \"siRNA knockdown in primary monocytes, ChIP, co-IP to map interaction domains, retroviral rescue in IRF8-/- cell line\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal Co-IP with domain mapping plus ChIP and functional rescue, single lab\",\n      \"pmids\": [\"21228327\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"IRF-8 extinguishes neutrophil production and promotes DC lineage commitment in both myeloid and lymphoid progenitors in a cell-intrinsic manner; retroviral expression of IRF-8 in GMP (which does not normally generate DCs) suppressed neutrophil production and increased DC output.\",\n      \"method\": \"Irf8-/- competitive bone marrow reconstitution, retroviral overexpression in multiple progenitor types\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — cell-intrinsic competitive reconstitution plus gain-of-function in multiple progenitor types, replicated findings\",\n      \"pmids\": [\"22238324\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"IRF8 acts as a negative regulator of osteoclastogenesis; TLR ligands and cytokines induce IRF8 expression to inhibit osteoclast differentiation, placing IRF8 in a feedback inhibition circuit.\",\n      \"method\": \"Loss-of-function analysis in osteoclast differentiation assays, IRF8 induction by TLR ligands/cytokines\",\n      \"journal\": \"Annals of the New York Academy of Sciences\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — review/commentary format with limited primary experimental detail in abstract\",\n      \"pmids\": [\"22082370\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"G-CSF and GM-CSF (MDSC-inducing factors) downregulate IRF-8 expression in myeloid cells via STAT3- and STAT5-dependent pathways, and IRF-8 overexpression attenuates MDSC accumulation, establishing STAT3/STAT5 as writers that suppress IRF8 to drive MDSC development.\",\n      \"method\": \"IRF-8 overexpression mouse model, Irf8-/- phenotyping, pathway analysis of STAT3/STAT5 signaling\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic models plus defined cytokine pathways, single lab\",\n      \"pmids\": [\"24091328\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"IRF8 and PU.1 form a complex that controls plasma cell differentiation by concurrently promoting BCL6 and PAX5 expression and repressing AID and BLIMP-1; IRF8-PU.1 complex functions reciprocally to IRF4.\",\n      \"method\": \"Genetic loss-of-function (conditional KO), reporter assay, gene expression profiling\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — conditional KO with transcriptional target analysis, single lab\",\n      \"pmids\": [\"25288399\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Wnt/β-catenin signaling activates Irf8 expression in normal hematopoiesis, and IRF8 in turn limits oncogenic β-catenin functions; combined Irf8 deletion and constitutive β-catenin activation drive CML blast crisis, establishing a cross-talk circuit.\",\n      \"method\": \"Mouse genetics (Irf8 conditional KO combined with activated β-catenin alleles), BCR-ABL CML model\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic epistasis with defined in vivo phenotypes, single lab\",\n      \"pmids\": [\"24101380\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"IRF8 directly activates genes involved in multiple steps of autophagy in macrophages, promotes autophagosome formation and lysosomal fusion; Irf8-/- macrophages accumulate SQSTM1 and ubiquitin-bound proteins and fail to clear Listeria monocytogenes via autophagy.\",\n      \"method\": \"Irf8-/- macrophage analysis, ChIP (IRF8 at autophagy gene promoters), autophagic flux assay, bacterial clearance assay\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP plus functional autophagic flux and bacterial clearance assays in KO context, single lab, multiple methods\",\n      \"pmids\": [\"25775030\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Icsbp/IRF8 is required to terminate emergency granulopoiesis by repressing Fap1 and Gas2 and activating Fanconi C and F genes; loss of Icsbp results in sustained granulocyte production, resistance to Fas-induced apoptosis, increased β-catenin activity, and accelerated progression to AML.\",\n      \"method\": \"Icsbp-/- mouse emergency granulopoiesis model, gene expression analysis, apoptosis assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — KO mouse model with mechanistic target gene analysis, single lab\",\n      \"pmids\": [\"26683374\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"SIRT1 physically interacts with IRF8 and deacetylates it in macrophages; LPS treatment decreases SIRT1 expression and increases IRF8 expression, and LPS-induced IRF8 expression is abrogated when SIRT1 is specifically deleted.\",\n      \"method\": \"Co-immunoprecipitation, immunofluorescence, SIRT1 conditional KO macrophages\",\n      \"journal\": \"Innate immunity\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — Co-IP plus KO phenotype, single lab\",\n      \"pmids\": [\"28008797\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"IRF8 controls Th9 differentiation through a transcription factor complex of IRF8, IRF4, PU.1, and BATF that binds DNA and activates Il9 transcription; IRF8 also dimerizes with ETV6 to repress Il4 expression.\",\n      \"method\": \"In vitro and in vivo Th9 differentiation assays (IRF8-deficient mice), ChIP, co-IP for complex components\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP and Co-IP with defined complex, KO phenotype in vivo, single lab\",\n      \"pmids\": [\"29233972\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"IRF8 governs the transcription of Naip genes (NLRC4 inflammasome sensors for flagellin and T3SS components) in macrophages, enabling NLRC4 inflammasome activation; IRF8 is required for optimal NLRC4 inflammasome activation against Salmonella, Burkholderia, and Pseudomonas but is dispensable for NLRP3, AIM2, and Pyrin inflammasome activation.\",\n      \"method\": \"Irf8-/- bone marrow-derived macrophages, infection assays, RNA-seq, ChIP, caspase-1 activation assay\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — KO macrophages with multiple pathogens, ChIP for direct binding, selective inflammasome specificity established with multiple orthogonal methods\",\n      \"pmids\": [\"29576451\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Cell-intrinsic IRF8 is required for NK cell-mediated protection against MCMV; during viral exposure, NK cells upregulate IRF8 through IL-12 signaling via STAT4, which promotes epigenetic remodeling of the Irf8 locus; IRF8 then promotes NK cell proliferation by inducing cell-cycle genes and directly controlling Zbtb32.\",\n      \"method\": \"Cell-intrinsic KO, IL-12 signaling analysis, STAT4 requirement, epigenetic analysis of Irf8 locus, MCMV infection model\",\n      \"journal\": \"Immunity\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — cell-intrinsic KO with defined signaling pathway (IL-12/STAT4/IRF8/Zbtb32), epigenetic and functional readouts\",\n      \"pmids\": [\"29858012\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Tumor-produced granulocyte-stimulating factor downregulates IRF8 in cDC progenitors, resulting in reduced cDC1 development and impaired anti-tumor CD8+ T-cell responses.\",\n      \"method\": \"Mouse tumor models (breast, pancreatic), bone marrow progenitor analysis, IRF8 expression measurement, CD8+ T-cell functional assays\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — mechanistic pathway identified in vivo with functional immune readout, single lab\",\n      \"pmids\": [\"29593283\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"A +41-kb Irf8 enhancer transiently accessible in cDC1 progenitors is required for induction of Irf8 in CDPs and cDC1 fate specification; a separate +32-kb Irf8 enhancer is required for cDC1 maturation but not specification. CRISPR/Cas9 deletion of these enhancers distinguishes their roles.\",\n      \"method\": \"CRISPR/Cas9 genome editing of enhancers, chromatin profiling (ATAC-seq), in vivo DC development analysis\",\n      \"journal\": \"Nature immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — CRISPR enhancer deletion with chromatin profiling, two enhancers functionally distinguished\",\n      \"pmids\": [\"31406378\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"An Nfil3-Zeb2-Id2 genetic circuit controls the switch from the +41-kb to +32-kb Irf8 enhancer during cDC1 development; Nfil3 is required for the transition from Zeb2hi/Id2lo to Zeb2lo/Id2hi CDPs (earliest committed cDC1 progenitors), excluding pDC potential.\",\n      \"method\": \"Single-cell RNA sequencing of CDPs, genetic epistasis analysis (Nfil3, Zeb2, Id2 KO combinations), enhancer accessibility\",\n      \"journal\": \"Nature immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — scRNA-seq plus genetic epistasis with multiple KO combinations, replicated in companion paper\",\n      \"pmids\": [\"31406377\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"IRF8 deletion in committed cDC1 cells (via Xcr1-Cre) causes their transcriptional, functional, and epigenetic reprogramming into cDC2-like cells, indicating IRF8 is continuously required to maintain cDC1 identity; this conversion was independent of Irf4.\",\n      \"method\": \"Xcr1-Cre conditional IRF8 deletion, RNA-seq, ATAC-seq, functional assays\",\n      \"journal\": \"Immunity\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — conditional KO in committed cells with transcriptome and chromatin accessibility profiling, epistasis with Irf4\",\n      \"pmids\": [\"35830859\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"ZMYND8 directly activates IRF8 through lineage-specific enhancers in AML; ZMYND8 occupancy at IRF8 enhancers requires BRD4 (a transcription coactivator), and ZMYND8 binds to the ET domain of BRD4 via its chromatin reader cassette, establishing an IRF8-MEF2D transcriptional circuit as an AML dependency.\",\n      \"method\": \"ChIP-seq (ZMYND8, BRD4, IRF8 enhancers), in vitro and in vivo ZMYND8 KO, protein interaction mapping\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — ChIP-seq with mechanistic protein-interaction mapping and in vivo functional validation, single lab\",\n      \"pmids\": [\"34358447\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"A RUNX-CBFβ-driven enhancer 56 kb downstream of the Irf8 transcription start site controls Irf8 expression throughout the myeloid lineage; deletion of this enhancer decreases IRF8 throughout myeloid progenitors, resulting in loss of cDC progenitors and overproduction of Ly6C+ monocytes, and demonstrates that IRF8 expression level (high/low/null) dose-dependently directs cDC1/monocyte/neutrophil fate via distinct sets of enhancers.\",\n      \"method\": \"In vivo CRISPR enhancer deletion, scRNA-seq, ATAC-seq, flow cytometric lineage analysis\",\n      \"journal\": \"Nature immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — in vivo enhancer deletion with chromatin profiling and dose-dependent lineage analysis\",\n      \"pmids\": [\"33603226\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Brd4 forms a complex with IRF8/PU.1 and binds to IRF8 and PU.1 binding motifs on Naip promoters to maintain Naip expression; Brd4-deficient macrophages show impaired NLRC4 inflammasome activation and reduced Naip transcription.\",\n      \"method\": \"Co-IP (Brd4/IRF8/PU.1 complex), ChIP, Brd4-/- macrophage infection assay, RNA-seq\",\n      \"journal\": \"The Journal of cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP for complex plus ChIP and KO functional assay, single lab\",\n      \"pmids\": [\"33535228\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"IRF8 promotes STING-mediated innate immune responses in monocytes through a transcription-independent mechanism: in uninfected cells IRF8 is inactive (IAD sequestered by N- and C-terminal tails); upon cGAS-STING pathway activation, IRF8 is phosphorylated at Serine 151, enabling its IRF-association domain to bind STING, promoting STING polymerization and TBK1-mediated phosphorylation of STING and IRF3.\",\n      \"method\": \"Phospho-mutant analysis, co-IP, IRF8-deficient monocytes, HSV-1 infection model, STING polymerization assay\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — phospho-mutant with biochemical reconstitution (STING polymerization, TBK1 phosphorylation), disease-relevant patient correlation, multiple orthogonal methods\",\n      \"pmids\": [\"35973990\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"TAM-specific IRF8 is required for tumor-associated macrophages to present cancer cell antigens and promote CTL exhaustion in tumors; TAM-specific IRF8 deletion prevented exhaustion of cancer-reactive CTLs and suppressed tumor growth.\",\n      \"method\": \"TAM-specific conditional IRF8 deletion, antigen presentation assays, CTL exhaustion markers, tumor growth assay\",\n      \"journal\": \"Immunity\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — cell-type-specific conditional KO with defined antigen presentation and exhaustion phenotypes, in vivo tumor suppression\",\n      \"pmids\": [\"36288724\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"IRF8 suppresses T-ALL by inhibiting the PI3K/AKT signaling pathway; FTO (m6A demethylase) binds to m6A sites in the 3' UTR of IRF8 mRNA and promotes its degradation, silencing IRF8 in T-ALL cells.\",\n      \"method\": \"IRF8 overexpression/KO in T-ALL cells, PI3K/AKT signaling analysis, m6A-seq, RIP-seq (FTO binding to IRF8 mRNA), FTO inhibition in vivo\",\n      \"journal\": \"Advanced science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — m6A-seq and RIP-seq identification of post-transcriptional regulation plus functional pathway validation, single lab\",\n      \"pmids\": [\"36478193\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"IRF8 binds stepwise to enhancer regions in postnatal microglia together with Sall1 and PU.1, reaching maximum binding after day 14; IRF8 binding correlates with stepwise increases in chromatin accessibility preceding microglial-specific transcriptome initiation; IRF8 is also required for microglial-specific DNA methylation patterns. Constitutive or postnatal Irf8 deletion causes loss of microglial identity and gain of disease-associated microglia (DAM)-like gene expression.\",\n      \"method\": \"ChIP-seq, ATAC-seq, scRNA-seq, scATAC-seq, conditional Irf8 deletion (constitutive and postnatal), bisulfite sequencing (DNA methylation), 5xFAD model\",\n      \"journal\": \"Nature immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — multiple orthogonal epigenomic methods (ChIP-seq, ATAC-seq, methylation) plus conditional KO with single-cell resolution\",\n      \"pmids\": [\"39313544\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"IRF8 deficiency causes cDC2 heterogeneity through two distinct pathways: a lymphoid-primed IRF8hi pathway (marked by CD123 and BTLA) carries pDC, cDC1, and DC2 trajectories, while a common myeloid IRF8lo pathway (SIRPA+) generates DC3s and monocytes; DC3s expand to replace DC2s in human partial IRF8 deficiency.\",\n      \"method\": \"Human IRF8-deficiency allelic series, high-dimensional flow cytometry, in vitro differentiation from human stem cells\",\n      \"journal\": \"Immunity\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — human genetic loss-of-function series with in vitro differentiation and high-dimensional analysis\",\n      \"pmids\": [\"32735845\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"IRF8 promotes NLRP3 inflammasome activation during Gram-negative bacterial infection by mediating phosphorylation of IRF3, which is required for Ifnb transcription; IFN-β in turn triggers caspase-11-dependent NLRP3 inflammasome activation. IRF8 was previously shown to be dispensable for caspase-11-mediated NLRP3 activation during LPS transfection.\",\n      \"method\": \"IRF8-/- bone marrow-derived macrophages, caspase-1/caspase-11 activation assays, Gram-negative bacterial infection, IRF3 phosphorylation analysis\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — KO macrophages with defined signaling pathway (IRF8→IRF3 phosphorylation→IFN-β→caspase-11→NLRP3), single lab\",\n      \"pmids\": [\"32205422\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"IRF8 inhibits osteoclastogenesis; an IRF8 G388S mutation promotes osteoclastogenesis and fails to inhibit NFATc1-dependent transcriptional activation; IRF8 constitutively binds regulatory regions of thousands of genes in osteoclast precursors and its loss enhances osteoclast-specific transcripts.\",\n      \"method\": \"Functional osteoclastogenesis assay, NFATc1 reporter assay, ChIP-seq in osteoclast precursors, Irf8+/- mouse alveolar bone analysis\",\n      \"journal\": \"Journal of bone and mineral research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — ChIP-seq plus functional mutant assay plus in vivo mouse phenotype, single lab\",\n      \"pmids\": [\"30840779\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"PU.1 and IRF8 bind to an Ets/IRF composite element (EICE) in the distal promoter of human NLRP3, controlling its monocytic lineage-specific expression; knockdown of PU.1 and/or IRF8 downregulates NLRP3 expression and markedly diminishes LPS-induced IL-1β release.\",\n      \"method\": \"Reporter assay, EMSA, ChIP, siRNA knockdown in THP-1 and primary macrophages\",\n      \"journal\": \"Frontiers in immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — EMSA and ChIP with functional KD readout, single lab\",\n      \"pmids\": [\"33897697\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"IRF8 and PU.1 are required for microglial activation; both factors directly target each other's gene transcription in a positive feedback loop; IRF8 and PU.1 cooperatively bind composite IRF-ETS motifs on microglial activation-related genes, verified biochemically by synergistic binding to composite-motif DNA.\",\n      \"method\": \"Post-developmental conditional deletion in microglia, 3D fluorescence imaging, ChIP, biochemical DNA-binding assay\",\n      \"journal\": \"Protein & cell\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — conditional KO with biochemical binding confirmation, single lab\",\n      \"pmids\": [\"30484118\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"miR-22 directly targets the 3' UTR of Irf8 mRNA for post-transcriptional repression, controlling DC subset differentiation; miR-22 overexpression enhanced cDC generation at the expense of pDCs while reducing Irf8 mRNA abundance.\",\n      \"method\": \"Luciferase reporter assay (miR-22 binding Irf8 3' UTR), miR-22 overexpression/knockdown during DC development\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — luciferase reporter with mutagenesis plus gain/loss-of-function in DC development, single lab\",\n      \"pmids\": [\"23251709\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"IRF8 (ICSBP) is an IFN-γ-inducible transcription factor that operates through combinatorial interactions with PU.1, IRF-1, IRF-2, IRF-3, IRF-4, BATF, NFAT, and other partners via its IRF-association domain (IAD) and DNA-binding domain, binding ISRE, EICE, and GAS elements to control myeloid lineage commitment (promoting monocytes/macrophages/DCs while suppressing neutrophils), DC subset specification (requiring lineage-specific +41-kb and +32-kb Irf8 enhancers activated by RUNX-CBFβ or E-protein circuits), NK and B cell maturation, inflammasome activation (by transcribing Naip genes for NLRC4), autophagy gene expression, and microglial identity (by establishing enhancer chromatin accessibility and DNA methylation), and also functions transcription-independently by being phosphorylated at Ser151 to associate with STING and promote its polymerization and TBK1-mediated innate immune signaling.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"IRF8 (ICSBP) is an IFN-γ-inducible transcription factor that serves as a master regulator of myeloid and dendritic cell fate, hematopoietic homeostasis, and innate immunity [#0, #1]. Its induction is driven by STAT1 acting through a palindromic IFN response element in the Irf8 promoter [#1], and it operates through three functional modules: a DNA-binding domain, a transcriptional repressor domain, and an IRF-association domain (IAD) that mediates combinatorial partnerships with other transcription factors [#2]. Through these partnerships—with PU.1, IRF-1, IRF-2, IRF-3, IRF-4, BATF, NFAT, and the Ets factor TEL—IRF8 binds ISRE, EICE, and composite Ets/IRF elements to either activate or repress targets depending on partner context, including TEL/HDAC3-mediated repressive feedback at the ISRE [#2, #9, #11, #21, #24, #33]. At the lineage level IRF8 drives differentiation of monocytes, macrophages, and dendritic cells while extinguishing neutrophil/granulocyte production, with dose-dependent enhancer usage (a RUNX-CBFβ-driven +56-kb enhancer for the broad myeloid program, transient +41-kb and +32-kb enhancers for cDC1 specification versus maturation) determining cDC1, monocyte, or neutrophil fate, and continuous IRF8 activity required to maintain committed cDC1 identity [#4, #25, #37, #38, #39, #41]. IRF8 functions as a myeloid tumor suppressor that antagonizes BCR-ABL-driven myeloproliferation by activating cell-cycle and pro-apoptotic programs (p15Ink4b, Blimp-1, acid ceramidase) and repressing growth-promoting targets (c-Myc, bcl-2, β-catenin via Gas2), and its loss accelerates progression to blast crisis and AML [#6, #12, #13, #15, #22, #23, #31]. In innate immunity IRF8 transcribes Naip genes to license NLRC4 inflammasome activation, drives autophagy gene expression for bacterial clearance, and cooperates with IRF3 for IFN-β induction [#30, #34, #42, #24]. Beyond transcription, IRF8 acts non-transcriptionally in the cGAS-STING pathway: phosphorylation at Ser151 releases its IAD to bind STING, promoting STING polymerization and TBK1-mediated signaling [#43]. IRF8 also establishes and maintains microglial identity through stepwise enhancer activation, chromatin accessibility, and DNA methylation alongside Sall1 and PU.1 [#46, #51]. Human IRF8 deficiency produces a graded loss of dendritic cell subsets [#47].\",\n  \"teleology\": [\n    {\n      \"year\": 1993,\n      \"claim\": \"Establishing how IRF8 is itself controlled, the discovery that its promoter carries a STAT1-bound IFN response element defined IRF8 as a downstream effector of IFN-γ signaling.\",\n      \"evidence\": \"Gel shift, reporter assays, and antibody supershift on the murine ICSBP promoter\",\n      \"pmids\": [\"8321202\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not address IRF8's own transcriptional targets\", \"Other inducing signals beyond IFN-γ/STAT1 not mapped\"]\n    },\n    {\n      \"year\": 1995,\n      \"claim\": \"Dissecting the protein into a DNA-binding domain, a repressor domain, and an IRF-association domain explained how IRF8 could act through partner-dependent combinatorial assemblies.\",\n      \"evidence\": \"Domain deletion mutagenesis, GAL4/VP16 fusions, EMSA, and co-IP with IRF-1 and IRF-2\",\n      \"pmids\": [\"7768900\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not establish in vivo physiological partners\", \"Structural basis of IAD interaction not resolved\"]\n    },\n    {\n      \"year\": 1996,\n      \"claim\": \"The null mouse demonstrated that IRF8 is essential for hematopoietic homeostasis, linking its loss to a CML-like myeloproliferative syndrome and immunodeficiency.\",\n      \"evidence\": \"ICSBP-/- knockout mice with bone marrow transfer and phenotypic analysis\",\n      \"pmids\": [\"8861914\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not identify the direct target genes underlying myeloproliferation\", \"Cell-intrinsic versus environmental contributions not separated\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Gain-of-function and target studies showed IRF8 actively drives macrophage differentiation while repressing granulocyte genes and is the principal activator of IL-12 p40, defining its myeloid lineage-instructive role.\",\n      \"evidence\": \"Retroviral rescue of ICSBP-/- progenitors, differentiation assays, and IL-12 p40 promoter reporter/binding assays\",\n      \"pmids\": [\"10981959\", \"10861061\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full set of macrophage versus granulocyte target genes incomplete\", \"Mechanism of partner selection at distinct promoters unresolved\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Demonstrating IRF8 downregulation by BCR-ABL and its suppression of CML in vivo established IRF8 as a bona fide myeloid tumor suppressor.\",\n      \"evidence\": \"Retroviral co-expression with BCR-ABL, colony formation, and murine bone marrow transplantation\",\n      \"pmids\": [\"10648600\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct transcriptional targets mediating tumor suppression not yet defined at this stage\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Mechanistic dissection revealed IRF8's tumor-suppressive output operates through repression of c-Myc (via Blimp-1/METS), bcl-2, and PTPN13/Fap-1, and activation of p15Ink4b, linking IRF8 to growth arrest and apoptosis sensitivity.\",\n      \"evidence\": \"Conditional ICSBP/ER systems, reporter assays, EMSA, and apoptosis assays in BCR/ABL-transformed cells\",\n      \"pmids\": [\"12933588\", \"14656881\", \"14976051\", \"18195016\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct versus indirect target relationships partly inferred\", \"Single-lab findings for several targets\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Identifying partner-dependent activity—NFAT and TEL/HDAC3 associations, plus the requirement for DNA binding and IRF interaction—explained how IRF8 toggles between activation and repression at the same elements.\",\n      \"evidence\": \"Mass spectrometry of ISRE-bound proteins, co-IP, ChIP, reporter assays, and mutant rescue in DC differentiation\",\n      \"pmids\": [\"12370291\", \"12876285\", \"12393459\", \"12417340\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Determinants of repressive versus activating partner recruitment not fully defined\", \"Some interactions characterized in single labs\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Knockout and chimera studies established IRF8's selective requirement for CD8α+ DC and plasmacytoid DC development, anchoring its role in DC subset specification.\",\n      \"evidence\": \"ICSBP-/- mouse and bone marrow chimera analysis with flow cytometry and RT-PCR\",\n      \"pmids\": [\"12461077\", \"12393690\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Enhancer-level control of subset specification not yet known\", \"Did not resolve dose-dependence of fate decisions\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"The BXH2 R294C IAD mutation linked a specific lesion to loss of partner interaction, IL-12 defects, and myeloproliferation, proving the IAD is functionally essential in vivo.\",\n      \"evidence\": \"Positional cloning, sequencing, transactivation reporter assays, and DC subset phenotyping in BXH2 mice\",\n      \"pmids\": [\"15781580\", \"18055870\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Why pDC development is spared while CD8α+ DC is lost not fully explained mechanistically\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Direct binding studies in B-cell and myeloid contexts showed IRF8 regulates lineage transcription factors (Sfpi1/PU.1, Ebf1) and forms composite complexes with PU.1 and IRF-2, formalizing its combinatorial logic in lineage specification.\",\n      \"evidence\": \"ChIP, reporter assays, and mutant rescue in IRF8-/- HSCs; EMSA with phosphorylation mutants\",\n      \"pmids\": [\"18799728\", \"17200120\", \"28008797\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Post-translational control of partner recruitment (Tyr/Ser phosphorylation, deacetylation) only partly mapped\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Multiple studies positioned IRF8 within signaling circuits controlling its abundance—STAT3/STAT5 and tumor-derived G-CSF suppress it to drive MDSC/cDC defects, while Wnt/β-catenin activates it—linking IRF8 levels to immune and oncogenic outcomes.\",\n      \"evidence\": \"Genetic models, cytokine pathway analysis, tumor models, and β-catenin epistasis\",\n      \"pmids\": [\"24091328\", \"29593283\", \"24101380\", \"29233972\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Quantitative thresholds of IRF8 needed for each outcome not defined here\", \"Several single-lab mechanisms\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"IRF8 was shown to directly transcribe autophagy genes and (with PU.1) Naip/NLRP3 inflammasome components, extending its role from lineage control to effector innate immune functions.\",\n      \"evidence\": \"ChIP, autophagic flux and bacterial clearance assays, infection assays, and caspase activation in Irf8-/- macrophages\",\n      \"pmids\": [\"25775030\", \"29576451\", \"33897697\", \"32205422\", \"33535228\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Selectivity for NLRC4 versus other inflammasomes mechanistically partial\", \"Brd4 contribution to Naip control single-lab\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Cell-intrinsic studies defined an IL-12/STAT4/IRF8/Zbtb32 axis driving NK cell proliferation and antiviral protection through epigenetic remodeling of the Irf8 locus, broadening IRF8 beyond myeloid lineages.\",\n      \"evidence\": \"Cell-intrinsic KO, STAT4 requirement, epigenetic profiling, and MCMV infection\",\n      \"pmids\": [\"29858012\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct NK-specific IRF8 target genome not fully cataloged\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"CRISPR enhancer deletion and single-cell genomics established a dose- and enhancer-dependent code (+56-kb, +41-kb, +32-kb; Nfil3-Zeb2-Id2 circuit) that times Irf8 expression to specify versus maintain cDC1 identity.\",\n      \"evidence\": \"CRISPR enhancer deletion, ATAC-seq, scRNA-seq, genetic epistasis, and conditional deletion in committed cDC1\",\n      \"pmids\": [\"31406378\", \"31406377\", \"41\", \"35830859\", \"33603226\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Trans-factors reading each enhancer not all identified\", \"How IRF8 dose is sensed at target promoters unresolved\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Identifying ZMYND8-BRD4 activation of IRF8 enhancers and an IRF8-MEF2D circuit revealed how IRF8 is co-opted as an AML dependency, connecting enhancer regulation to leukemic survival.\",\n      \"evidence\": \"ChIP-seq, protein interaction mapping, and in vitro/in vivo ZMYND8 knockout\",\n      \"pmids\": [\"34358447\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Therapeutic tractability of the circuit not addressed in this synthesis\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"The discovery that Ser151-phosphorylated IRF8 binds STING to promote its polymerization revealed a transcription-independent role in cGAS-STING/TBK1 innate immune signaling.\",\n      \"evidence\": \"Phospho-mutant analysis, co-IP, STING polymerization assays, and HSV-1 infection of IRF8-deficient monocytes\",\n      \"pmids\": [\"35973990\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Kinase responsible for Ser151 phosphorylation not identified here\", \"Interplay between transcriptional and non-transcriptional roles unresolved\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Multi-omic epigenomic profiling showed IRF8 stepwise establishes microglial enhancer accessibility and DNA methylation with Sall1 and PU.1, and is continuously required to maintain microglial identity versus disease-associated states.\",\n      \"evidence\": \"ChIP-seq, ATAC-seq, scRNA/scATAC-seq, bisulfite sequencing, and conditional deletion in the 5xFAD model\",\n      \"pmids\": [\"39313544\", \"30484118\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism coupling IRF8 binding to DNA methylation changes not defined\", \"Relevance to human microglial disease not directly tested\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Cell-type-specific deletion and post-transcriptional regulation studies placed IRF8 at the interface of tumor immunity—TAM IRF8 drives CTL exhaustion, while FTO/m6A and miR-22 tune IRF8 levels to control differentiation and malignancy.\",\n      \"evidence\": \"TAM-specific and tumor conditional KO, antigen presentation/exhaustion assays, m6A-seq, RIP-seq, and luciferase 3'UTR reporters\",\n      \"pmids\": [\"36288724\", \"36478193\", \"23251709\", \"32735845\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Context-dependent pro- versus anti-tumor roles of IRF8 not fully reconciled\", \"Some post-transcriptional mechanisms single-lab\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How IRF8's transcriptional and non-transcriptional (STING) activities are coordinated within a single cell, and what upstream kinases and dose-sensing mechanisms integrate the diverse signaling inputs into context-specific enhancer choice, remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unified model linking Ser151/Tyr phosphorylation events to transcriptional output\", \"Kinase(s) and full PTM code not defined\", \"Determinants of activator-versus-repressor partner selection incompletely mapped\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [2, 4, 5, 9, 19, 34, 41, 46]},\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [2, 17, 18, 19, 49]},\n      {\"term_id\": \"GO:0140098\", \"supporting_discovery_ids\": []},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [43]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [2, 9, 19]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [43]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [5, 7, 34, 35, 47]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [1, 2, 19, 41]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [4, 25, 37, 41, 46]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [6, 16, 40, 44]},\n      {\"term_id\": \"R-HSA-9612973\", \"supporting_discovery_ids\": [30]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [43, 48]},\n      {\"term_id\": \"R-HSA-4839726\", \"supporting_discovery_ids\": [46, 37, 41]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"PU.1\", \"IRF1\", \"IRF2\", \"IRF3\", \"IRF4\", \"BATF\", \"NFATC1\", \"STING1\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":9,"faith_total":9,"faith_pct":100.0}}